Difference between revisions of "HAEM5:Volunteer Assignments and Opportunities"

[unchecked revision]

Revision as of 16:23, 16 April 2024

Welcome!

A new version of the Heme/Lymphoid book (5th edition) is in beta form on the WHO website with publication of a final form anticipated in 2024; we're aligning the related CCGA content to the new structure.

For assignments, please see the "Author" column below (highlighted blue).

If empty (no name is present), please volunteer to create content for that disease!
If "PENDING" is present, the original author of that disease page is currently being contacted about revising the content.

To volunteer, please [Contact us] with your page of interest.
Note - "NEW (No Prior)" in the 4th edition columns means either the disease is a new entity in the 5th edition or the disease was present in the 4th edition without content previously added.

WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (5th Edition) Content
Disease (5th Edition)	Page Type	Author (5th Edition) (Note: please indicate trainees in parentheses)	Date Assigned to Author (5th Edition)	Target Completion Date (5th Edition)	Content Status (5th Edition)(Pending or Complete)	Date Completed by Author (5th Edition)	Associate Editor	Date of Last Editor Review (5th Edition)	Notes (5th Edition)	Correlated Prior Disease Name (4th Edition)	Correlated Prior Author (4th Edition)	Prior Content Status (4th Edition)(Pending or Complete)	Prior Date of Last Editor Review (4th Edition)	Prior Notes (4th Edition)
CHAPTER 2 (MYELOID PROLIFERATIONS AND NEOPLASMS)
Clonal haematopoiesis	Disease	Meenakshi Mehrotra	4/8/24		Pending		Fabiola Quintero-Rivera (FQR)			NEW (No Prior)	NEW (No Prior)	NEW (No Prior)	NEW (No Prior)	NEW (No Prior)
Clonal cytopenias of undetermined significance	Disease						FQR			NEW (No Prior)	NEW (No Prior)	NEW (No Prior)	NEW (No Prior)	NEW (No Prior)
Chronic myeloid leukaemia	Disease	PENDING					FQR			Chronic Myeloid Leukemia (CML), BCR-ABL1 Positive	Jack Reid, MD (University of California, Irvine) Mark Evans, MD (University of California, Irvine) Fabiola Quintero-Rivera, MD (University of California, Irvine)	Complete	Date page was created
Chronic neutrophilic leukaemia	Disease	PENDING					FQR			Chronic Neutrophilic Leukemia (CNL)	Anamaria Munteanu, MD, Ph.D, Harbor-UCLA Medical Center, Joseph J. Merlo Jr, MD. Ph.D, Ashion Analytics, Fabiola Quintero-Rivera, University of California Irvine **contributed equally	Complete	Date page was created
Chronic eosinophilic leukaemia	Disease	PENDING					FQR			Chronic Eosinophilic Leukemia, Not Otherwise Specified	Chelsea D. Kramish; Daynna J.Wolff	complete/pending faculty review
Polycythaemia vera	Disease	PENDING					FQR			Polycythemia Vera (PV)	Gokce A. Toruner, MD, PhD UT MD Anderson Cancer Center	Complete
Essential thrombocythaemia	Disease	PENDING					FQR			Essential Thrombocythemia (ET)	Rebecca Smith, PhD, Director, Genetics Associates, Nashville, TN	Complete
Primary myelofibrosis	Disease	PENDING					FQR			Primary Myelofibrosis (PMF)	T. Niroshi Senaratne, UCLA	Complete	8/4/2020 before submission
Juvenile myelomonocytic leukaemia	Disease	PENDING					FQR			Juvenile Myelomonocytic Leukemia (JMML)	Sarah Rapisardo, PhD, FACMG \| Assistant Professor, Pathology Associate Director \| Division of Molecular Pathology, Genetics and Genomics Duke University Health System Clinical Laboratories	PENDING importing content and reference formatting		FQR has emailed SR several times, last 4/20/22
Myeloproliferative neoplasm, NOS	Disease	PENDING					FQR			Myeloproliferative Neoplasm (MPN), Unclassifiable	Thomas Lee, MD, PhD, University of California, Los Angeles	Complete
Cutaneous mastocytosis	Disease	PENDING					FQR			Cutaneous Mastocytosis	S. Shawn Liu, MD, PhD and Thuy Phung, MD, PhD	Complete
Systemic mastocytosis	Disease	PENDING					FQR			Systemic Mastocytosis	Abdullah Osme, MD, University Hospitals Cleveland Medical Center, Case Western Reserve University Shashi Shetty, Ph.D. FACMG, FCCMG, University Hospitals Cleveland Medical Center, Case Western Reserve University	Complete
Mast cell sarcoma	Disease	PENDING					FQR			Mast Cell Sarcoma	Jordan Lowery, MD and Thuy Phung, MD, PhD Department of Pathology, University of South Alabama, Mobile, AL	Complete
Myelodysplastic neoplasm with low blasts and 5q deletion	Disease	PENDING					FQR			Myelodysplastic Syndrome (MDS) with Isolated del(5q)	Xiaolin Hu, Ph.D; Teresa Smolarek, Ph.D, FACMG	Complete
Myelodysplastic neoplasm with low blasts and SF3B1 mutation	Disease	PENDING					FQR			NEW (No Prior)	NEW (No Prior)	NEW (No Prior)	NEW (No Prior)	NEW (No Prior)
Myelodysplastic neoplasm with biallelic TP53 inactivation	Disease	Eric McGinnis (assigned to new 5th edition page - FQR is this reviewed?)					FQR			NEW (No Prior)	NEW (No Prior)	NEW (No Prior)	NEW (No Prior)	NEW (No Prior)
Myelodysplastic neoplasm with low blasts	Disease						FQR			NEW (No Prior)	NEW (No Prior)	NEW (No Prior)	NEW (No Prior)	NEW (No Prior)
Myelodysplastic neoplasm, hypoplastic	Disease						FQR			NEW (No Prior)	NEW (No Prior)	NEW (No Prior)	NEW (No Prior)	NEW (No Prior)
Myelodysplastic neoplasm with increased blasts	Disease	PENDING					FQR			Myelodysplastic Syndrome (MDS) with Excess Blasts	Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG Division of Human Genetics, Cincinnati Children's Hospital Medical Center	Complete
Childhood myelodysplastic neoplasm with low blasts	Disease	PENDING					FQR			Refractory Cytopenia of Childhood	Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG Division of Human Genetics, Cincinnati Children's Hospital Medical Center	Complete
Childhood myelodysplastic neoplasm with increased blasts	Disease	PENDING					FQR			Refractory Cytopenia of Childhood	Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG Division of Human Genetics, Cincinnati Children's Hospital Medical Center	Complete
Chronic myelomonocytic leukaemia	Disease	PENDING					FQR			Chronic Myelomonocytic Leukemia (CMML)	Linsheng Zhang, MD, PhD	Complete
Myelodysplastic/myeloproliferative neoplasm with neutrophilia	Disease	PENDING					FQR			Atypical Chronic Myeloid Leukemia (aCML), BCR-ABL1 Negative	Linsheng Zhang, MD, PhD	Complete
Myelodysplastic/myeloproliferative neoplasm with SF3B1 mutation and thrombocytosis	Disease	PENDING					FQR			Myelodysplastic/Myeloproliferative Neoplasms with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T)	Anamaria Munteanu, MD, Ph.D, Harbor-UCLA Medical Center, Fabiola Quintero-Rivera, University of California Irvine	Complete	Date page was created
Myelodysplastic/myeloproliferative neoplasm, NOS	Disease	PENDING					FQR			Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN), Unclassifiable	Ruth MacKinnon PhD Victorian Cancer Cytogenetics Service Melbourne, Australia	Complete
Acute promyelocytic leukaemia with PML::RARA fusion	Disease	PENDING					Jennelle Hodge (JH)/ Malini Sathanoori (MS)			Acute Promyelocytic Leukemia (APL) with PML-RARA	Yiming Zhong, Ph.D., Megan Piazza, Ph.D., and Shashi Shetty, Ph.D.	Complete	03/01/2021-MS (re-review)
Acute myeloid leukaemia with RUNX1::RUNX1T1 fusion	Disease	PENDING					JH_MS			Acute Myeloid Leukemia (AML) with t(8;21)(q22;q22.1); RUNX1-RUNX1T1	Christine Bryke, MD Beth Israel Deaconess Medical Center, Boston, MA	Complete	04/26/2021-MS (re-review)
Acute myeloid leukaemia with CBFB::MYH11 fusion	Disease	PENDING					JH_MS			Acute Myeloid Leukemia (AML) with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Christine Bryke, MD Beth Israel Deaconess Medical Center, Boston, MA	Complete	03/01/2021-MS (re-review)
Acute myeloid leukaemia with DEK::NUP214 fusion	Disease	PENDING					JH_MS			Acute Myeloid Leukemia (AML) with t(6;9)(p23;q34.1); DEK-NUP214	Jennelle C. Hodge, PhD, FACMG	Complete	02/24/2021-MS (re-review)
Acute myeloid leukaemia with RBM15::MRTFA fusion	Disease	PENDING					JH_MS			Acute Myeloid Leukemia (AML) Megakaryoblastic with t(1;22)(p13.3;q13.1);RBM15-MKL1	Jennelle C. Hodge, PhD, FACMG	Complete
Acute myeloid leukaemia with BCR::ABL1 fusion	Disease	PENDING					JH_MS			Acute Myeloid Leukemia (AML) with BCR-ABL1	Kay Weng Choy MBBS, Monash Medical Centre	Complete
Acute myeloid leukaemia with KMT2A rearrangement	Disease	PENDING					JH_MS			Acute Myeloid Leukemia (AML) with t(9;11)(p21.3;q23.3); KMT2A-MLLT3	Megan Piazza, Ph.D., Yiming Zhong, Ph.D., Shashi Shetty, Ph.D.	Complete	03/01/2021-MS (re-review)
Acute myeloid leukaemia with MECOM rearrangement	Disease	PENDING					JH_MS			Acute Myeloid Leukemia (AML) with inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2);GATA2, MECOM	Gordana Raca MD PhD, University of Southern California, Los Angeles	Complete		Need permission for figure? Update WHO?
Acute myeloid leukaemia with NUP98 rearrangement	Disease	Eric McGinnis, MD	12/20/23				JH_MS			NEW (No Prior)	NEW (No Prior)	NEW (No Prior)	NEW (No Prior)	NEW (No Prior)
Acute myeloid leukaemia with NPM1 mutation	Disease	PENDING					JH_MS			Acute Myeloid Leukemia (AML) with Mutated NPM1	Xinjie Xu, PhD, FACMG	Complete		Add WHO reference
Acute myeloid leukaemia with CEBPA mutation	Disease	PENDING					JH_MS			Acute Myeloid Leukemia (AML) with Biallelic Mutations of CEBPA	Paul Defazio, MSc, Monash Health	Complete
Acute myeloid leukaemia, myelodysplasia-related	Disease	PENDING					JH_MS			Acute Myeloid Leukemia (AML) with Myelodysplasia-Related Changes	Fei Yang, MD, FACMG Oregon Health & Science University	Complete
Acute myeloid leukaemia with other defined genetic alterations	Disease						JH_MS			NEW (No Prior)	NEW (No Prior)	NEW (No Prior)	NEW (No Prior)	NEW (No Prior)
Acute myeloid leukaemia with minimal differentiation	Disease	PENDING					JH_MS			Acute Myeloid Leukemia (AML) with Minimal Differentiation	Celeste Eno, PhD, Cedars Sinai Medical Center, Los Angeles, Fabiola Quintero-Rivera, MD, FACMG, University of California Irvine	Complete
Acute myeloid leukaemia without maturation	Disease	PENDING					JH_MS			Acute Myeloid Leukemia (AML) without Maturation	Jennelle C. Hodge, PhD, FACMG	Complete
Acute myeloid leukaemia with maturation	Disease	PENDING					JH_MS			Acute Myeloid Leukemia (AML) with Maturation	Jennelle C. Hodge, PhD, FACMG	Complete
Acute basophilic leukaemia	Disease	PENDING					JH_MS			Acute Basophilic Leukemia	Ashwini Yenamandra PhD FACMG	Complete
Acute myelomonocytic leukaemia	Disease	PENDING					JH_MS			Acute Myelomonocytic Leukemia	Fei Yang, MD, FACMG Oregon Health & Science University	Complete
Acute monocytic leukaemia	Disease	PENDING					JH_MS			Acute Monoblastic and Monocytic Leukemia	Fei Yang, MD, FACMG Oregon Health & Science University	Complete
Acute erythroid leukaemia	Disease	PENDING					JH_MS			Pure Erythroid Leukemia	Ashwini Yenamandra PhD FACMG	Complete
Acute megakaryoblastic leukaemia	Disease	PENDING					JH_MS			Acute Megakaryoblastic Leukemia (AMKL)	Fei Yang, MD, FACMG Oregon Health & Science University	Complete
Myeloid sarcoma	Disease	PENDING					JH_MS			Myeloid Sarcoma	Yalda Naeini, MD, School of Medicine at University of California Los Angeles Fabiola Quintero-Rivera, MD, FACMG, School of Medicine at University of California Irvine	Complete
RESOLVE 4th edition AML-Related NON-WHO entities content	Acute Myeloid Leukemia (AML) with Mutated FLT3 + Acute Myeloid Leukemia (AML) with NUP214-ABL1 + Acute Myeloid Leukemia (AML) with t(4;12)(q12;p13); CHIC2-ETV6	ISSUE- FIX Resolve Non-WHO entities
Myeloid neoplasm post cytotoxic therapy	Disease	PENDING					JH_MS			Therapy-Related Myeloid Neoplasms	Shawn A. Silver, DO, Shashi Shetty, Ph.D.	Complete		Check reference format
Myeloid neoplasms associated with germline predisposition	Disease	PENDING					JH_MS			Multiple pages including overview page (Myeloid Neoplasms with Germline Predisposition - Compendium of Cancer Genome Aberrations (ccga.io)) and 6 disease pages ( HAEM4:Acute Myeloid Leukaemia with Germline CEBPA Mutation, HAEM4:Myeloid Neoplasms with Germline DDX41 Mutation, HAEM4:Myeloid Neoplasms with Germline ETV6 Mutation, HAEM4:Myeloid Neoplasms with Germline GATA2 Mutation, HAEM4:Myeloid Neoplasms with Germline RUNX1 Mutation, HAEM4:Myeloid Neoplasms with Germline ANKRD26 Mutation)	See links from instructions on the 5th edition page	Complete	Most were re-reviewed by MS on 03/02/2021	For page Acute Myeloid Leukaemia with Germline CEBPA Mutation - Note by MS of "Review completed, awaiting some clarification from JH - 07/04/2022"
Myeloid proliferations associated with Down syndrome	Disease	PENDING					JH_MS			MERGE 3 PAGES --> Transient Abnormal Myelopoiesis (TAM) Associated with Down Syndrome + Transient Abnormal Myelopoiesis (TAM) Associated with Down Syndrome + Myeloid Leukemia Associated with Down Syndrome	Linda D Cooley, MD, MBA, Children's Mercy Hospital, Kansas City, MO	Complete (all three pages)
Myeloid/lymphoid neoplasm with PDGFRA rearrangement	Disease	PENDING					FQR			Myeloid/Lymphoid Neoplasms with PDGFRA Rearrangement	Jay Alden, DO	Complete
Myeloid/lymphoid neoplasm with PDGFRB rearrangement	Disease	PENDING					FQR			Myeloid/Lymphoid Neoplasms with PDGFRB Rearrangement	Christopher Sullivan, MD, MPH and Daynna J. Wolff, PhD	Complete
Myeloid/lymphoid neoplasm with FGFR1 rearrangement	Disease	PENDING					FQR			Myeloid/Lymphoid Neoplasms with FGFR1 Rearrangement	Yanna Ding, MD PhD	Complete
Myeloid/lymphoid neoplasm with JAK2 rearrangement	Disease	ISSUE- FIX Resolve Non-WHO entities					FQR			Myeloid/Lymphoid Neoplasms with PCM1-JAK2 + consider a non-WHO page Myeloid/Lymphoid Neoplasms with ETV6-JAK2 (Myeloid/Lymphoid Neoplasms with ETV6-JAK2 - Compendium of Cancer Genome Aberrations (ccga.io)) + another non-WHO page Myeloid/Lymphoid Neoplasms with BCR-JAK2 (Myeloid/Lymphoid Neoplasms with BCR-JAK2 - Compendium of Cancer Genome Aberrations (ccga.io) ) - both non-WHO pages are authored by trainee Lauren Crowson-Hindman and Daynna Wolff	Jessica Snider, M.D. and Daynna J. Wolff, PhD + non-WHO pages by trainee Lauren Crowson-Hindman and Daynna Wolff	Complete
Myeloid/lymphoid neoplasm with FLT3 rearrangement	Disease						FQR			NEW (No Prior)	NEW (No Prior)	NEW (No Prior)	NEW (No Prior)	NEW (No Prior)
Myeloid/lymphoid neoplasm with ETV6::ABL1 fusion	Disease						FQR			NEW (No Prior)	NEW (No Prior)	NEW (No Prior)	NEW (No Prior)	NEW (No Prior)
Myeloid/lymphoid neoplasms with other tyrosine kinase fusion genes	Disease						FQR			NEW (No Prior)	NEW (No Prior)	NEW (No Prior)	NEW (No Prior)	NEW (No Prior)
Mixed-phenotype acute leukaemia with BCR::ABL1 fusion	Disease	Tracy Tucker, PhD, FCCMG	4/6/24		Pending		JH_MS			Mixed Phenotype Acute Leukemia (MPAL) with t(9;22)(q34.1;q11.2); BCR-ABL1	Tracy Tucker, PhD, FCCMG	Complete
Mixed-phenotype acute leukaemia with KMT2A rearrangement	Disease	Tracy Tucker, PhD, FCCMG	4/6/24		Pending		JH_MS			Mixed Phenotype Acute Leukemia (MPAL) with t(v;11q23.3); KMT2A Rearranged	Tracy Tucker, PhD, FCCMG	Complete
Acute leukaemia of ambiguous lineage with other defined genetic alterations	Disease						JH_MS			NEW (No Prior)	NEW (No Prior)	NEW (No Prior)	NEW (No Prior)	NEW (No Prior)
Mixed-phenotype acute leukaemia, B/myeloid	Disease	PENDING					JH_MS			Mixed Phenotype Acute Leukemia (MPAL), B/Myeloid, Not Otherwise Specified	Priyatharsini Nirmalanantham, MD and Shashi Shetty, PhD	Complete
Mixed-phenotype acute leukaemia, T/myeloid	Disease	PENDING					JH_MS			Mixed Phenotype Acute Leukemia (MPAL), T/Myeloid, Not Otherwise Specified	Narsis Attar, MD, PhD, Fabiola Quintero-Rivera, MD University of California, Irvine	Complete
Mixed-phenotype acute leukaemia, rare types	Disease	PENDING					JH_MS			Mixed-Phenotype Acute Leukemia, Not Otherwise Specified (NOS), Rare Types	Elicia Goodale, MD, Medical University of South Carolina Daynna Wolff, PhD, Medical University of South Carolina	PENDING
Acute leukaemia of ambiguous lineage, NOS	Disease						JH_MS			NEW (No Prior)	NEW (No Prior)	NEW (No Prior)	NEW (No Prior)	NEW (No Prior)
Acute undifferentiated leukaemia	Disease	PENDING					JH_MS			Acute Undifferentiated Leukemia	Amelia Nakanishi, MD and Shashi Shetty, PhD	Complete		Check reference format
CHAPTER 3 (HISTIOCYTIC/DENRITIC CELL NEOPLASMS)
Mature plasmacytoid dendritic cell proliferation associated with myeloid neoplasm	Disease						Greg Corboy (GC)			NEW (No Prior)	NEW (No Prior)	NEW (No Prior)	NEW (No Prior)	NEW (No Prior)
Blastic plasmacytoid dendritic cell neoplasm	Disease	PENDING					GC			Blastic Plasmacytoid Dendritic Cell Neoplasm	Hao Liu, MD and Daynna J. Wolff, PhD	Complete		Previously within myeloid section under JH/MS editors
Langerhans cell histiocytosis	Disease	PENDING					GC			Langerhans Cell Histiocytosis	Dr Malaika Perchard BSci(MedSci), MBBS, FRACP, FRCPA, (Paediatric Haematologist) Pathology Queensland	Complete	5/19/2022	Date completed by author: 04/28/2022
Langerhans cell sarcoma	Disease	PENDING					GC			Langerhans Cell Sarcoma	Dr Malaika Perchard BSci(MedSci), MBBS, FRACP, FRCPA, (Paediatric Haematologist) Pathology Queensland	Complete	5/19/2022	Date completed by author: 04/28/2022
Indeterminate dendritic cell tumour	Disease						GC			NEW (No Prior)	NEW (No Prior)	NEW (No Prior)	NEW (No Prior)	NEW (No Prior)
Interdigitating dendritic cell sarcoma	Disease						GC			NEW (No Prior)	NEW (No Prior)	NEW (No Prior)	NEW (No Prior)	NEW (No Prior)
Juvenile xanthogranuloma	Disease						GC			NEW (No Prior)	NEW (No Prior)	NEW (No Prior)	NEW (No Prior)	NEW (No Prior)
Erdheim-Chester disease	Disease						GC			NEW (No Prior)	NEW (No Prior)	NEW (No Prior)	NEW (No Prior)	NEW (No Prior)
Rosai-Dorfman Disease	Disease						GC			NEW (No Prior)	NEW (No Prior)	NEW (No Prior)	NEW (No Prior)	NEW (No Prior)
ALK-positive histiocytosis	Disease						GC			NEW (No Prior)	NEW (No Prior)	NEW (No Prior)	NEW (No Prior)	NEW (No Prior)
Histiocytic sarcoma	Disease	PENDING					GC			Histiocytic Sarcoma	Marie-France Gagnon, MD, Mayo Clinic, Xinjie Xu, PhD FACMG, Mayo Clinic	Complete	10/01/2021	Date completed by author: 10/01/2021
CHAPTER 4 (B-CELL LYMPHOID PROLIFERATIONS AND LYMPHOMAS)
Reactive B-cell rich lymphoid proliferations that can mimic lymphoma	Disease						GC			NEW (No Prior)	NEW (No Prior)	NEW (No Prior)	NEW (No Prior)	NEW (No Prior)
IgG4-related disease	Disease						GC			NEW (No Prior)	NEW (No Prior)	NEW (No Prior)	NEW (No Prior)	NEW (No Prior)
Unicentric Castleman disease	Disease						GC			NEW (No Prior)	NEW (No Prior)	NEW (No Prior)	NEW (No Prior)	NEW (No Prior)
Idiopathic multicentric Castleman disease	Disease						GC			NEW (No Prior)	NEW (No Prior)	NEW (No Prior)	NEW (No Prior)	NEW (No Prior)
KSHV/HHV8-associated multicentric Castleman disease	Disease	PENDING					GC			Multicentric Castleman Disease	Sudha Arumugam, MD	Complete	01/24/2022	Date completed by author: 01/24/2022
B-lymphoblastic leukaemia/lymphoma	Disease	PENDING					Holli Drendel (HD)			B-Lymphoblastic Leukemia/Lymphoma, Not Otherwise Specified	Holli Drendel	PENDING
B-lymphoblastic leukaemia/lymphoma with high hyperdiploidy	Disease	PENDING					HD			B-Lymphoblastic Leukemia/Lymphoma with Hyperdiploidy	Afia Hasnain, MBBS, PhD; Yassmine Akkari, PhD, FACMG	PENDING
B-lymphoblastic leukaemia/lymphoma with hypodiploidy	Disease	PENDING					HD			B-Lymphoblastic Leukemia/Lymphoma with Hypodiploidy	Ashwini Yenamandra PhD FACMG Lisa Smith PhD FACMG Yassmine Akkari PhD FACMG	Complete
B-lymphoblastic leukaemia/lymphoma with iAMP21	Disease	Holli Drendel			?Complete? Looks like tables need more editing.		HD			B-Lymphoblastic Leukemia/Lymphoma with iAMP21 [but was completed as a 5th edition page by Holli]	Holli M. Drendel, PhD, FACMGG, Carolinas Pathology Group, Charlotte	?Complete
B-lymphoblastic leukaemia/lymphoma with BCR::ABL1 fusion	Disease	PENDING					HD			B-Lymphoblastic Leukemia/Lymphoma with t(9;22)(q34.1;q11.2); BCR-ABL1	Afia Hasnain, MBBS, PhD; Yassmine Akkari, PhD, FACMG	PENDING
B-lymphoblastic leukaemia/lymphoma with BCR::ABL1-like features	Disease	PENDING					HD			B-Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like	Mark G. Evans, MD, University of California, Irvine Fabiola Quintero-Rivera, MD, University of California, Irvine	Complete
B lymphoblastic leukaemia/lymphoma with KMT2A rearrangement	Disease	PENDING					HD			B-Lymphoblastic Leukemia/Lymphoma with t(v;11q23.3); KMT2A-Rearranged	Yassmine Akkari Nicolas Millan	PENDING
B lymphoblastic leukaemia/lymphoma with ETV6::RUNX1 fusion	Disease	PENDING					HD			B lymphoblastic leukaemia/lymphoma with ETV6::RUNX1 fusion	Marilena Melas, PhD; Yassmine Akkari, PhD, FACMG Cancer Category/Type B-Lymphoblastic Leukemia/Lymphoma	PENDING
B-lymphoblastic leukaemia/lymphoma with ETV6::RUNX1-like features	Disease						HD			NEW (No Prior)	NEW (No Prior)	NEW (No Prior)	NEW (No Prior)	NEW (No Prior)
B lymphoblastic leukaemia/lymphoma with TCF3::PBX1 fusion	Disease	PENDING					HD			B-Lymphoblastic Leukemia/Lymphoma with t(1;19)(q23;p13.3); TCF3-PBX1	Binu Porath, PhD. Vanderbilt University Medical Center, Nashville, TN Linda D. Cooley, MD, MBA. Children's Mercy Kansas City, Kansas City, MO	PENDING
B lymphoblastic leukaemia/lymphoma with IGH::IL3 fusion	Disease	PENDING					HD			B-Lymphoblastic Leukemia/Lymphoma with t(5;14)(q31.1;q32.1); IGH/IL3	Binu Porath, PhD. Vanderbilt University Medical Center, Nashville, TN Linda D. Cooley, MD, MBA. Children's Mercy Kansas City, Kansas City, MO	PENDING
B lymphoblastic leukaemia/lymphoma with TCF3::HLF fusion	Disease						HD			NEW (No Prior)	NEW (No Prior)	NEW (No Prior)	NEW (No Prior)	NEW (No Prior)
B-lymphoblastic leukaemia/lymphoma with other defined genetic alterations	Disease						HD			NEW (No Prior)	NEW (No Prior)	NEW (No Prior)	NEW (No Prior)	NEW (No Prior)
B-lymphoblastic leukaemia/lymphoma, NOS	Disease						HD			NEW (No Prior)	NEW (No Prior)	NEW (No Prior)	NEW (No Prior)	NEW (No Prior)
RESOLVE 4th edition ALL-Related NON-WHO entities content	B-Lymphoblastic Leukemia/Lymphoma with t(4;14)(q35.2;q32); IGH/DUX4 + B-Lymphoblastic Leukemia/Lymphoma with dic(9;12)(p13;p13); PAX5/ETV6 + B-Lymphoblastic Leukemia/Lymphoma with ZNF384 Rearrangements + B-Lymphoblastic Leukemia/Lymphoma with IKZF1 Deletions + B-Lymphoblastic Leukemia/Lymphoma with TCF3 Rearrangements - Excluding t(1;19) and t(12;19) + B-Lymphoblastic Leukemia/Lymphoma with dic(9;20)(p13;q11)	ISSUE- FIX Resolve Non-WHO entities									ISSUE - FIX
Monoclonal B-cell lymphocytosis	Disease	PENDING; Shashirekha Shetty					Shivani Golem (SG)			Monoclonal B-cell Lymphocytosis	Tsigab Bahta Hagos (trainee) / Shashirekha Shetty	PENDING, 4/30/2024		Assigned 12/19/2022 with completion date of 1/19/2023
Chronic lymphocytic leukaemia/small lymphocytic lymphoma	Disease	Jaime Nagy, PhD, University of Iowa Renee Eigsti, MD, Pathology Services of Kalamazoo Honey Reddi, PhD, Belay Diagnostics			Complete		SG			Already converted to 5th edition	Jamie Nagy, PhD, University of Iowa Honey Reddi, PhD
Hairy cell leukaemia	Disease						SG			Hairy Cell Leukemia	Snehal Patel, MD, PhD	Complete
Splenic marginal zone lymphoma	Disease						SG			Splenic Marginal Zone Lymphoma	Snehal Patel, MD, PhD	Complete
Splenic diffuse red pulp small B-cell lymphoma	Disease						SG			Splenic Diffuse Red Pulp Small B-cell Lymphoma	Snehal Patel, MD, PhD	Complete
Splenic B-cell lymphoma/leukaemia with prominent nucleoli	Disease						SG			Hairy Cell Leukemia Variant	Snehal Patel, MD, PhD	Complete
Lymphoplasmacytic lymphoma	Disease	PENDING					SG			(1) Lymphoplasmacytic Lymphoma + (2) Waldenstrom Macroglobulinemia	(1 and 2) Kapitolina Semenova, MD, Jack Reid, MD, Fabiola Quintero-Rivera, MD Departments of Pathology, Laboratory Medicine, and Pediatrics, Division of Genetic and Genomic Medicine, University of California, Irvine (UCI)	Complete	4/12/2023 by FQR
Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue	Disease	PENDING					SG			Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT Lymphoma)	Whayoung Lee, MD (trainee), Fabiola Quintero-Rivera, MD, FACMG* Department of Pathology and Laboratory Medicine and *Pediatrics, School of Medicine, University of California Irvine (UCI)	Complete	4/12/23 by FQR
Primary cutaneous marginal zone lymphoma	Disease						SG			NEW (No Prior)	NEW (No Prior)	NEW (No Prior)	NEW (No Prior)	NEW (No Prior)
Nodal marginal zone lymphoma	Disease	PENDING					SG			Nodal Marginal Zone Lymphoma	Andrew Ly, DO and Shivani Golem, PhD, FACMG	Complete	5/28/2021
Paediatric nodal marginal zone lymphoma	Disease	PENDING					SG			Paediatric Nodal Marginal Zone Lymphoma	* Kathleen M. Schieffer, PhD * Ruthann Pfau, PhD	Complete	11/11/2020
In situ follicular B-cell neoplasm	Disease	Rachel D. Burnside, PhD, MBA, FACMGG	7/28/2023		Pending		SG			In Situ Follicular Neoplasia	Rachel D. Burnside, PhD, MBA, FACMGG	Pending
Follicular lymphoma	Disease	Rachel D. Burnside, PhD, MBA, FACMGG	7/28/2023		Pending		SG		Author also needs to correlate with 4th edition disease "Testicular Follicular Lymphoma", which is no longer a separate entity	(1) Follicular Lymphoma + (2) Testicular Follicular Lymphoma	(1 and 2) Ruthann Pfau, PhD, FACMG, Nationwide Children's Hospital Rachel D. Burnside, PhD, MBA, FACMG, University of Florida	Pending
Paediatric-type follicular lymphoma	Disease	PENDING					SG			Paediatric-Type Follicular Lymphoma	Kathleen M. Schieffer, PhD Ruthann Pfau, PhD, FACMG	Complete	8/16/2020
Duodenal-type follicular lymphoma	Disease	Rachel D. Burnside, PhD, MBA, FACMGG	7/28/2023		Pending		SG			Duodenal-Type Follicular Lymphoma	No prior content
Primary cutaneous follicle centre lymphoma	Disease	PENDING					SG			Primary Cutaneous Follicle Centre Lymphoma	Linlin Gao, MD, PhD and Shivani Golem, PhD, FACMG	Complete	09/10/2022
In situ mantle cell neoplasm	Disease	PENDING					SG			In Situ Mantle Cell Neoplasia	Rina Kansal, MD; Versiti Blood Center of Wisconsin	Complete	7/26/2022
Mantle cell lymphoma	Disease	PENDING					SG			Mantle Cell Lymphoma	Mahsa Khanlari, MD and Zhenya Tang, MD, PhD The University Of Texas MD Anderson Cancer Center, Department of Hematopathology, Houston, Texas	Pending		Target completion date 8/15/20
Leukaemic non-nodal mantle cell lymphoma	Disease						SG			NEW (No Prior)	NEW (No Prior)	NEW (No Prior)	NEW (No Prior)	NEW (No Prior)
Transformations of indolent B-cell lymphomas	Disease						SG		Include content on chronic myelomonocytic leukemia in transformation and refractory anaemia with excess blasts in transformation	NEW (No Prior)	NEW (No Prior)	NEW (No Prior)	NEW (No Prior)	NEW (No Prior)
Diffuse large B-cell lymphoma, NOS	Disease	PENDING					GC			Diffuse Large B-cell Lymphoma, Not Otherwise Specified	Ashwini Yenamandra, PhD FACMG, Vanderbilt University Medical Center	Pending		Requested to update 14022022
T-cell/histiocyte-rich large B-cell lymphoma	Disease						GC			NEW (No Prior)	NEW (No Prior)	NEW (No Prior)	NEW (No Prior)	NEW (No Prior)
Diffuse large B-cell lymphoma / high grade B-cell lymphoma with MYC and BCL2 rearrangements	Disease	PENDING					GC			High-Grade B-cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements	Kate Berry, MBBS, BBus (Hons), Pathology Queensland	Complete	24/02/2022
ALK-positive large B-cell lymphoma	Disease	PENDING					GC			ALK-Positive Large B-cell Lymphoma	Manando Nakasaki, MD, PhD (University of California, Irvine) Fabiola Quintero-Rivera, MD, FACMG (University of California, Irvine)	Pending		Nakasaki Manando removed March 2022 due to no progress/contact 1y. Added Nakasaki Manando back n 8/29/22 based on newer email communication (Jennelle's note). 2021 template added. FQR emailed Manando on 4/12/23
Large B-cell lymphoma with IRF4 rearrangement	Disease	PENDING					GC			Large B-cell Lymphoma with IRF4 Rearrangement	Afia Hasnain, MBBS, PhD	Complete	5/26/2021
High grade B-cell lymphoma with 11q aberrations	Disease	PENDING					GC			Burkitt-Like Lymphoma with 11q Aberration	Lauren Shealy, MD, Medical University of South Carolina Daynna Wolff, PhD, Medical University of South Carolina	Comlete	27/01/2022
Lymphomatoid granulomatosis	Disease						GC			NEW (No Prior)	NEW (No Prior)	NEW (No Prior)	NEW (No Prior)	NEW (No Prior)
EBV-positive diffuse large B-cell lymphoma	Disease	Fnu Monika (trainee) + Andrew Siref as mentor	3/22/24		Pending		GC			NEW (No Prior)	NEW (No Prior)	NEW (No Prior)	NEW (No Prior)	NEW (No Prior)
Diffuse large B-cell lymphoma associated with chronic inflammation	Disease						GC			NEW (No Prior)	NEW (No Prior)	NEW (No Prior)	NEW (No Prior)	NEW (No Prior)
Fibrin-associated large B-cell lymphoma	Disease	PENDING					GC		Note: previously a subset DLBCL assoc with chronic inflam	Originally called Fibrin-Associated Diffuse Large B-cell Lymphoma; NEW (No Prior)	NEW (No Prior)	NEW (No Prior)	NEW (No Prior)	NEW (No Prior)
Fluid overload-associated large B-cell lymphoma	Disease						GC			NEW (No Prior)	NEW (No Prior)	NEW (No Prior)	NEW (No Prior)	NEW (No Prior)
Plasmablastic lymphoma	Disease	PENDING					GC			Plasmablastic Lymphoma	Mark Evans, MD (University of California, Irvine) Fabiola Quintero-Rivera, MD (University of California, Irvine)	Complete	28/03/2022
Primary large B-cell lymphoma of immune-privileged sites	Disease	PENDING					GC			(1) Diffuse Large B-cell Lymphoma, Not Otherwise Specified + (2) Primary Diffuse Large B-cell Lymphoma of the CNS	(1) Ashwini Yenamandra, PhD FACMG, Vanderbilt University Medical Center + (2) Laveniya Satgunaseelan, FRCPA, Department of Neuropathology, Royal Prince Alfred Hospital	(1) Pending + (2) Complete	(1) Not ready + (2) 03/28/22	For "Diffuse Large B-cell Lymphoma, Not Otherwise Specified" page from Ash, Greg requested to update 14022022
Primary cutaneous diffuse large B-cell lymphoma, leg type	Disease						GC			NEW (No Prior)	NEW (No Prior)	NEW (No Prior)	NEW (No Prior)	NEW (No Prior)
Intravascular large B-cell lymphoma	Disease	PENDING					GC			Intravascular Large B-cell Lymphoma	Kate Berry, MBBS, BBus (Hons), Pathology Queensland, Greg Corboy	Complete	9/1/22	Emailed 28/3/2022 for progress update
Primary mediastinal large B-cell lymphoma	Disease						GC			NEW (No Prior)	NEW (No Prior)	NEW (No Prior)	NEW (No Prior)	NEW (No Prior)
Mediastinal grey zone lymphoma	Disease						GC			NEW (No Prior)	NEW (No Prior)	NEW (No Prior)	NEW (No Prior)	NEW (No Prior)
High-grade B-cell lymphoma, NOS	Disease	PENDING					GC			High-Grade B-cell Lymphoma, Not Otherwise Specified (NOS)	Aiko Otsubo, PhD, Indiana University, Holli Drendel	Complete	16/11/2021
Burkitt lymphoma	Disease	PENDING					GC			Burkitt Lymphoma	Becky Leung, MBBS (Hons), BSc, Pathology Queensland	Complete	28/06/2021
Primary effusion lymphoma	Disease						GC			NEW (No Prior)	NEW (No Prior)	NEW (No Prior)	NEW (No Prior)	NEW (No Prior)
KSHV/HHV8-positive diffuse large B-cell lymphoma	Disease						GC			NEW (No Prior)	NEW (No Prior)	NEW (No Prior)	NEW (No Prior)	NEW (No Prior)
KSHV/HHV8-positive germinotropic lymphoproliferative disorder	Disease						GC			NEW (No Prior)	NEW (No Prior)	NEW (No Prior)	NEW (No Prior)	NEW (No Prior)
Hyperplasias arising in immune deficiency/dysregulation	Disease	FIX ISSUE! (on 5th edition page instructions say "encompassing non-destructive post-transplant lymphoproliferative disorders, among others"). "Non-Destructive Post-Transplant Lymphoproliferative Disorders" was a HAME4 page but no content. What are "among others" from HAEM4 to see if we need to pull prior content into 5th edition page.					GC
Polymorphic lymphoproliferative disorders arising in immune deficiency / dysregulation	Disease	FIX ISSUE! (on 5th edition page instructions say "This page was converted to the new template on 2023-12-07. The original page can be found at HAEM4:Polymorphic Post-Transplant Lymphoproliferative Disorders. Note: encompassing polymorphic PTLD, other iatrogenic immunodef-assoc lympho disorders, among others)"					GC			Polymorphic Post-Transplant Lymphoproliferative Disorders	Anna Shestakova, MD, PhD, Fellow, University of Utah/ARUP Laboratories Fabiola Quintero-Rivera, MD, Professor, University of California Irvine (UCI)	Completed	26/4/2022
EBV-positive mucocutaneous ulcer	Disease						GC			NEW (No Prior)	NEW (No Prior)	NEW (No Prior)	NEW (No Prior)	NEW (No Prior)
Lymphomas arising in immune deficiency / dysregulation	Disease	FIX ISSUE! (on 5th edition page instructions say "encompassing monomorphic PTLD, classic HL PTLD, lymphomas assoc with HIV infection, among others"					GC
Inborn error of immunity-associated lymphoid proliferations and lymphomas	Disease	FIX ISSUE! (on 5th edition page instructions say "Editor said this overview page is a match. [Immunodeficiency-Associated Lymphoproliferative Disorders] [Lymphoproliferative diseases associated with primary immune disorders]") - last link name above is not a known page in haem4 or haem5.					GC
Classic Hodgkin lymphoma	Disease	PENDING					GC		Note: author needs to merge Nodular Sclerosis Classic Hodgkin Lymphoma, Lymphocyte-Rich Classic Hodgkin Lymphoma, Mixed Cellularity Classic Hodgkin Lymphoma, Lymphocyte-Depleted Classic Hodgkin Lymphoma	(1) Lymphocyte-Rich Classic Hodgkin Lymphoma + (2) Nodular Sclerosis Classic Hodgkin Lymphoma + (3) Mixed Cellularity Classic Hodgkin Lymphoma + (4) Lymphocyte-Depleted Classic Hodgkin Lymphoma	(1) Patricia V. Hernandez, M.D., Washington University School of Medicine and Holli Drendel + (2) Xiaolin Hu, PhD, Sema4 OpCo Inc. + (3 and 4) Patricia V. Hernandez	Pending + Completed (03/21/22)	Not completed for checking (1, 3 and 4) + 03/21/22 (2)
Nodular lymphocyte predominant Hodgkin lymphoma	Disease						GC			NEW (No Prior)	NEW (No Prior)	NEW (No Prior)	NEW (No Prior)	NEW (No Prior)
Cold agglutinin disease	Disease						SG			NEW (No Prior)	NEW (No Prior)	NEW (No Prior)	NEW (No Prior)	NEW (No Prior)
IgM monoclonal gammopathy of undetermined significance	Disease						SG			NEW (No Prior)	NEW (No Prior)	NEW (No Prior)	NEW (No Prior)	NEW (No Prior)
Non-IgM monoclonal gammopathy of undetermined significance	Disease						SG			NEW (No Prior)	NEW (No Prior)	NEW (No Prior)	NEW (No Prior)	NEW (No Prior)
Monoclonal gammopathy of renal significance	Disease						SG			NEW (No Prior)	NEW (No Prior)	NEW (No Prior)	NEW (No Prior)	NEW (No Prior)
Immunoglobulin-related (AL) amyloidosis	Disease	PENDING					SG			Primary Amyloidosis	Heather E. Williams, PhD, MS, PgD, ErCLG	?PENDING
Monoclonal immunoglobulin deposition disease	Disease	PENDING					SG			Light Chain and Heavy Chain Deposition Disease	Chen Yang, MD, PhD, University of Michigan	Complete	10/15/2022
Mu heavy chain disease	Disease						SG			NEW (No Prior)	NEW (No Prior)	NEW (No Prior)	NEW (No Prior)	NEW (No Prior)
Gamma heavy chain disease	Disease	PENDING					SG			Gamma Heavy Chain Disease	Manisha Brahmbhatt-Sutariya Asst. Professor, Dept. of Pathology and Human Anatomy Technical Supervisor, Clinical Genetics Laboratory Loma Linda University, Medical Center, CA	Complete	5/26/2021
Alpha heavy chain disease	Disease						SG			NEW (No Prior)	NEW (No Prior)	NEW (No Prior)	NEW (No Prior)	NEW (No Prior)
Plasmacytoma	Disease	PENDING					SG		author needs to include Solitary plasmacytoma of bone, Extraosseous plasmacytoma (extramedullary) (v4 page did not have content on ccga)	NEW (No Prior) - no content on version 4 page "Plasmacytoma' originally assigned to Zhenya Tang	NEW (No Prior)	NEW (No Prior)	NEW (No Prior)	NEW (No Prior)
Plasma cell myeloma / multiple myeloma	Disease	PENDING					SG		Note: author needs to include Plasma_Cell_Myeloma_Variants content in this page	(1) Plasma Cell Myeloma + (2) Plasma Cell Myeloma Variants	(1) Huan Mo, MD, MS and Zhenya Tang, MD, PhD The University Of Texas MD Anderson Cancer Center, Department of Hematopathology, Houston, Texas + (2) Fariborz Rashid-Kolvear, PhD, FACMG, FCCMG	Pending
Plasma cell neoplasms with associated paraneoplastic syndrome	Disease	PENDING					SG		Note: author needs to include POEMS, TEMPI, and look for AESOP content	(1) POEMS Syndrome + (2) TEMPI Syndrome	(1 and 2) Sohini Anand, MBBS Tharanga Niroshini Senaratne, PhD	?PENDING
Disease (5th Edition)	Page Type	Author (5th Edition) (Note: please indicate trainees in parenthesis)	Date Assigned to Author (5th Edition)	Target Completion Date (5th Edition)	Content Status (5th Edition) (Pending or Complete)	Date Completed by Author (5th Edition)	Associate Editor	Date of Last Editor Review (5th Edition)	Notes (5th Edition)	Correlated Prior Disease Name (4th Edition)	Correlated Prior Author (4th Edition)	Prior Content Status (4th Edition) (Pending or Complete)	Prior Date of Last Editor Review (4th Edition)	Prior Notes (4th Edition)
CHAPTER 5 (T-CELL AND NK-CELL LYMPHOID PROLIFERATIONS AND LYMPHOMAS)
Kikuchi-Fujimoto disease	Disease						Sumi Kitahara (SK)			NEW (No Prior)	NEW (No Prior)	NEW (No Prior)	NEW (No Prior)	NEW (No Prior)
Autoimmune lymphoproliferative syndrome	Disease	Aviv Oren, MD (trainee), Karin Miller, MD	3/25/2024				SK			NEW (No Prior)	NEW (No Prior)	NEW (No Prior)	NEW (No Prior)	NEW (No Prior)
Indolent T-lymphoblastic proliferation	Disease						SK			NEW (No Prior)	NEW (No Prior)	NEW (No Prior)	NEW (No Prior)	NEW (No Prior)
T-lymphoblastic leukaemia / lymphoma, NOS	Disease						SK			NEW (No Prior)	NEW (No Prior)	NEW (No Prior)	NEW (No Prior)	NEW (No Prior)
Early T-precursor lymphoblastic leukaemia / lymphoma	Disease	Fei Yang, MD			Pending		SK			Early T-Cell Precursor Lymphoblastic Leukemia	Fei Yang, MD, FACMG, Kaiser Permanente Northwest	Pending
T-prolymphocytic leukaemia	Disease	Parastou Tizro, MD (trainee); Sumire Kitahara, MD	3/17/2024		Pending		SK			NEW (No Prior)	NEW (No Prior)	NEW (No Prior)	NEW (No Prior)	NEW (No Prior)
T-large granular lymphocytic leukaemia	Disease	Michelle Don, MD, MS	3/17/2024	6/30/24	Pending		SK			T-cell Large Granular Lymphocytic Leukemia	Michelle Don, MD, MS	Pending
NK-large granular lymphocytic leukaemia	Disease	Hailee St. Louis (trainee); Michelle Don, MD, MS	3/17/2024	6/30/24	Pending		SK			Chronic Lymphoproliferative Disorder of NK Cells	Michelle Don, MD	Pending
Adult T-cell leukaemia/lymphoma	Disease						SK			Adult T-cell Leukemia/Lymphoma	Prasad R. Kopparapu, PhD and Ferrin C. Wheeler, PhD, FACMG Vanderbilt University Medical Center	?Pending
Sezary syndrome	Disease	Daynna J. Wolff, PhD	3/22/2024				SK			Sézary Syndrome	Madison E. Hannay, DO, Medical University of South Carolina Tingting Barrett, MD, Medical University of South Carolina Daynna J. Wolff, PhD, Medical University of South Carolina	Pending
Aggressive NK-cell leukaemia	Disease	PENDING					SK			Aggressive NK-cell Leukemia	Shanelle De Lancy, MD, Shashirekha Shetty, PhD	?Pending
Primary cutaneous CD4-positive small or medium T-cell lymphoproliferative disorder	Disease	Amanda Xu, MD/MSc	3/19/2024		Pending		SK			NEW (No Prior)	NEW (No Prior)	NEW (No Prior)	NEW (No Prior)	NEW (No Prior)
Primary cutaneous acral CD8-positive T-cell lymphoproliferative disorder	Disease	Ahmed Eladely (trainee), Andrew Siref, MD	4/12/2024		Pending		SK			NEW (No Prior)	NEW (No Prior)	NEW (No Prior)	NEW (No Prior)	NEW (No Prior)
Mycosis fungoides	Disease	Daynna J. Wolff, PhD	3/22/2024				SK			Mycosis Fungoides	Jane Scribner, MD and Daynna J. Wolff, PhD	Pending
Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Lymphomatoid papulosis	Disease						SK			NEW (No Prior)	NEW (No Prior)	NEW (No Prior)	NEW (No Prior)	NEW (No Prior)
Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Primary cutaneous anaplastic large cell lymphoma	Disease	PENDING					SK			Primary Cutaneous Anaplastic Large Cell Lymphoma	Theresa Spivey, MD, Shashirekha Shetty, PhD	Pending
Subcutaneous panniculitis-like T-cell lymphoma	Disease	Raniah Alamri (Hemepath trainee)	3/19/2024		Pending		SK			NEW (No Prior)	NEW (No Prior)	NEW (No Prior)	NEW (No Prior)	NEW (No Prior)
Primary cutaneous gamma/delta T-cell lymphoma	Disease	Mahzad Azimpouran (trainee); Sumire Kitahara, MD					SK			NEW (No Prior)	NEW (No Prior)	NEW (No Prior)	NEW (No Prior)	NEW (No Prior)
Primary cutaneous CD8-positive aggressive epidermotropic cytotoxic T-cell lymphoma	Disease	Ahmed Eladely (trainee), Andrew Siref, MD	4/12/2024		Pending		SK			NEW (No Prior)	NEW (No Prior)	NEW (No Prior)	NEW (No Prior)	NEW (No Prior)
Primary cutaneous peripheral T-cell lymphoma, NOS	Disease						SK			NEW (No Prior)	NEW (No Prior)	NEW (No Prior)	NEW (No Prior)	NEW (No Prior)
Indolent T-cell lymphoma of the gastrointestinal tract	Disease						SK			Indolent T-cell Lymphoproliferative Disorder of the Gastrointestinal Tract	Derick Okwan-Duodu MD, PhD; Sumire Kitahara, MD	Pending
Indolent NK-cell lymphoproliferative disorder of the gastrointestinal tract	Disease						SK			NEW (No Prior)	NEW (No Prior)	NEW (No Prior)	NEW (No Prior)	NEW (No Prior)
Enteropathy-associated T-cell lymphoma	Disease	Fnu Monika, MBBS (trainee), Andrew Siref, MD	3/20/2024		Pending		SK			Enteropathy-Associated T-cell Lymphoma	Derick Okwan-Duodu, MD, PhD Sumire Kitahara, MD	Complete	1/21/2021
Monomorphic epitheliotropic intestinal T-cell lymphoma	Disease	Fnu Monika, MBBS (trainee), Andrew Siref, MD	3/20/2024		Pending		SK			Monomorphic Epitheliotropic Intestinal T-cell Lymphoma	Derick Okwan-Duodu MD, PhD; Sumire Kitahara, MD	Pending
Intestinal T-cell lymphoma, NOS	Disease						SK			Intestinal T-cell Lymphoma, Not Otherwise Specified (NOS)	Derick Okwan MD, PhD (Stanford Medicine, CA) Sumire Kitahara MD (Cedars-Sinai, CA)	Complete	9/26/2022
Hepatosplenic T-cell lymphoma	Disease	Forough Sargolzaeiaval (trainee); Michelle Don, MD, MS	3/19/2024	6/30/24	Pending		SK			Hepatosplenic T-cell Lymphoma	Michelle Don, MD, MS	Complete	1/21/2021
ALK-positive anaplastic large cell lymphoma	Disease	Miguel Gonzalez Mancera, MD (trainee) Sumire Kitahara, MD			Pending		SK			Anaplastic Large Cell Lymphoma, ALK-Positive	Miguel Gonzalez Mancera, MD Sumire Kitahara, MD Cedars-Sinai, Los Angeles, CA	Complete	09/23/2022
ALK-negative anaplastic large cell lymphoma	Disease	Miguel Gonzalez Mancera, MD (trainee) Sumire Kitahara, MD			Pending		SK			Anaplastic Large Cell Lymphoma, ALK-Negative	Miguel Gonzalez Mancera, MD Sumire Kitahara, MD Cedars-Sinai, Los Angeles, CA	Complete	09/23/2022
Breast implant-associated anaplastic large cell lymphoma	Disease	Lynne Abruzzo, MD, PhD	4/1/2024		Pending		SK			Breast Implant-Associated Anaplastic Large Cell Lymphoma	Derick Okwan-Duodu, MD, PhD; Sumire Kitahara, MD Cedars-Sinai Medical Center	Pending
Nodal TFH cell lymphoma, angioimmunoblastic-type	Disease	Rachel Burnside, PhD	7/28/2023		Pending		SK		prior authors not available	Angioimmunoblastic T-cell Lymphoma	Sara Akhavanfard, M.D., Ph.D. and Ruthann Pfau, Ph.D., FACMG	Pending
Nodal TFH cell lymphoma, follicular-type	Disease	Rachel Burnside, PhD	7/28/2023		Pending		SK			NEW (No Prior)	NEW (No Prior)	NEW (No Prior)	NEW (No Prior)	NEW (No Prior)
Nodal TFH cell lymphoma, NOS	Disease						SK			Nodal Peripheral T-cell Lymphoma with T Follicular Helper Phenotype	Hans Magne Hamnvåg, MD Kamran Mirza, MD, PhD	Pending
Peripheral T-cell lymphoma, NOS	Disease	Bo Hong, MD	6/25/2023				SK			NEW (No Prior)	NEW (No Prior)	NEW (No Prior)	NEW (No Prior)	NEW (No Prior)
EBV-positive nodal T- and NK-cell lymphoma	Disease	Fnu Monika, MBBS (trainee), Andrew Siref, MD	3/22/2024		Pending		SK			NEW (No Prior)	NEW (No Prior)	NEW (No Prior)	NEW (No Prior)	NEW (No Prior)
Extranodal NK/T-cell lymphoma	Disease	Amanda Xu, MD/MSc	3/19/2024		Pending		SK			NEW (No Prior)	NEW (No Prior)	NEW (No Prior)	NEW (No Prior)	NEW (No Prior)
Severe mosquito bite allergy	Disease						SK			NEW (No Prior)	NEW (No Prior)	NEW (No Prior)	NEW (No Prior)	NEW (No Prior)
Hydroa vacciniforme lymphoproliferative disorder	Disease						SK			NEW (No Prior)	NEW (No Prior)	NEW (No Prior)	NEW (No Prior)	NEW (No Prior)
Systemic chronic active EBV disease	Disease	Karin Miller, MD	3/25/2024				SK			NEW (No Prior)	NEW (No Prior)	NEW (No Prior)	NEW (No Prior)	NEW (No Prior)
Systemic EBV-positive T-cell lymphoma of childhood	Disease	Karin Miller, MD	3/25/2024				SK		prior authors not available	Systemic EBV-Positive T-cell Lymphoma of Childhood	Lisa A. Lansdon, PhD and Linda D. Cooley, MD, MBA	Complete	11/21/2021
CHAPTER 6 (STROMA-DERIVED NEOPLASMS OF LYMPHOID TISSUES)
Follicular dendritic cell sarcoma	Disease	PENDING					GC			Follicular Dendritic Cell Sarcoma	Anna Heimes Dillon, MD and Shivani Golem, PhD, FACMG	?Pending
EBV-positive inflammatory follicular dendritic cell sarcoma	Disease						GC			NEW (No Prior)	NEW (No Prior)	NEW (No Prior)	NEW (No Prior)	NEW (No Prior)
Fibroblastic reticular cell tumour	Disease						GC			NEW (No Prior)	NEW (No Prior)	NEW (No Prior)	NEW (No Prior)	NEW (No Prior)
Intranodal palisaded myofibroblastoma	Disease						GC			NEW (No Prior)	NEW (No Prior)	NEW (No Prior)	NEW (No Prior)	NEW (No Prior)
Littoral cell angioma	Disease						GC			NEW (No Prior)	NEW (No Prior)	NEW (No Prior)	NEW (No Prior)	NEW (No Prior)
Splenic hamartoma	Disease						GC			NEW (No Prior)	NEW (No Prior)	NEW (No Prior)	NEW (No Prior)	NEW (No Prior)
Sclerosing angiomatoid nodular transformation (SANT) of spleen	Disease						GC			NEW (No Prior)	NEW (No Prior)	NEW (No Prior)	NEW (No Prior)	NEW (No Prior)
CHAPTER 7 (GENETIC TUMOUR SYNDROMES)
Fanconi anaemia	Disease						NA			NEW (No Prior)	NEW (No Prior)	NEW (No Prior)	NEW (No Prior)	NEW (No Prior)
Bloom syndrome	Disease						NA			NEW (No Prior)	NEW (No Prior)	NEW (No Prior)	NEW (No Prior)	NEW (No Prior)
Ataxia-telangiectasia syndrome	Disease						NA			NEW (No Prior)	NEW (No Prior)	NEW (No Prior)	NEW (No Prior)	NEW (No Prior)
RASopathies	Disease						NA			NEW (No Prior)	NEW (No Prior)	NEW (No Prior)	NEW (No Prior)	NEW (No Prior)

Difference between revisions of "HAEM5:Volunteer Assignments and Opportunities"

Revision as of 16:23, 16 April 2024

Navigation menu

Search

@@ Line 1: / Line 1: @@
+Welcome!
+'''A new version of the Heme/Lymphoid book (5th edition) is in beta form on the WHO website with publication of a final form anticipated in 2024; we're aligning the related CCGA content to the new structure.'''
+*For assignments, please see the "Author" column below (highlighted blue).
+*If empty (no name is present), please volunteer to create content for that disease!
+*If "PENDING" is present, the original author of that disease page is currently being contacted about revising the content.
+*To volunteer, please '''[[Mailto:CCGA@cancergenomics.org <u>Contact us</u>]]''' with your page of interest.
+*Note - "NEW (No Prior)" in the 4th edition columns means either the disease is a new entity in the 5th edition or the disease was present in the 4th edition without content previously added.
+<br />
 {| class="wikitable" style="margin:auto"
-|+WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (4th Edition) Content
+|+<big>WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (5th Edition) Content</big>
 |-
-!Disease (5th Edition)!!Page Type!!Author!!Date Assigned to Author!!Target Completion Date!!Author Content (Pending or Complete)!!Date Completed by Author!!Associate Editor!!Date of Last Editor Review
+!Disease (5th Edition)!!Page Type!!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)!!Date Assigned to Author (5th Edition)
-!Correlated Prior Disease Name (4th Edition)!!Notes
+!Target Completion Date (5th Edition)!!Content Status (5th Edition)(Pending or Complete)!!Date Completed by Author (5th Edition)!!Associate Editor!!Date of Last Editor Review (5th Edition)!!Notes (5th Edition)
+!Correlated Prior Disease Name (4th Edition)
+!Correlated Prior Author (4th Edition)
+!Prior Content Status (4th Edition)(Pending or Complete)
+!Prior Date of Last Editor Review (4th Edition)
+!Prior Notes (4th Edition)
 |-
 |CHAPTER 2 (MYELOID PROLIFERATIONS AND NEOPLASMS)
@@ Line 11: / Line 29: @@
 ----<br />
 |
+----<br />
+|
+----<br />
+|
+----<br />
+|
+----<br />
+|
+----<br />
 |
+----<br />
 |
+----<br />
 |
+----<br />
 |
+----<br />
 |
+----<br />
 |
+----<br />
 |
+----<br />
 |-
-|Clonal haematopoiesis||Disease|| || || || || ||Fabiola Quintero-Rivera (FQR)||
+|[[HAEM5:Clonal haematopoiesis|Clonal haematopoiesis]]||Disease||Meenakshi Mehrotra
-| ||
+|4/8/24
+| ||Pending|| ||Fabiola Quintero-Rivera (FQR)|| ||
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
 |-
-|Clonal cytopenias of undetermined significance||Disease|| || || || || ||FQR||
+|[[HAEM5:Clonal cytopenias of undetermined significance|Clonal cytopenias of undetermined significance]]||Disease|| || || || || ||FQR|| ||
-| ||
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
 |-
-|Chronic myeloid leukaemia||Disease||Jack Reid, MD (University of California, Irvine)  Mark Evans, MD (University of California, Irvine)  Fabiola Quintero-Rivera, MD (University of California, Irvine)|| || || || ||FQR||
+|[[HAEM5:Chronic myeloid leukaemia|Chronic myeloid leukaemia]]||Disease||PENDING|| || || || ||FQR|| ||
-| ||
+|Chronic Myeloid Leukemia (CML), BCR-ABL1 Positive
+|Jack Reid, MD (University of California, Irvine)  Mark Evans, MD (University of California, Irvine)  Fabiola Quintero-Rivera, MD (University of California, Irvine)
+|Complete
+|Date page was created
+|
 |-
-|Chronic neutrophilic leukaemia||Disease||Anamaria Munteanu, MD, Ph.D**, Harbor-UCLA Medical Center, Joseph J. Merlo Jr, MD. Ph.D**, Ashion Analytics, Fabiola Quintero-Rivera, University of California Irvine  <nowiki>**</nowiki>contributed equally|| || || || ||FQR||
+|[[HAEM5:Chronic neutrophilic leukaemia|Chronic neutrophilic leukaemia]]||Disease||PENDING
-| ||
+| || || || ||FQR|| ||
+|Chronic Neutrophilic Leukemia (CNL)
+|Anamaria Munteanu, MD, Ph.D**, Harbor-UCLA Medical Center, Joseph J. Merlo Jr, MD. Ph.D**, Ashion Analytics, Fabiola Quintero-Rivera, University of California Irvine  <nowiki>**</nowiki>contributed equally
+|Complete
+|Date page was created
+|
 |-
-|Chronic eosinophilic leukaemia||Disease||Chelsea D. Kramish; Daynna J.Wolff  Pending Review*|| || || || ||FQR||
+|[[HAEM5:Chronic eosinophilic leukaemia|Chronic eosinophilic leukaemia]]||Disease||PENDING
-| ||
+| || || || ||FQR|| ||
+|Chronic Eosinophilic Leukemia, Not Otherwise Specified
+|Chelsea D. Kramish; Daynna J.Wolff
+|complete/pending faculty review
+|
+|
 |-
-|Polycythaemia vera||Disease||Gokce A. Toruner, MD, PhD  UT MD Anderson Cancer Center|| || || || ||FQR||
+|[[HAEM5:Polycythaemia vera|Polycythaemia vera]]||Disease||PENDING
-| ||
+| || || || ||FQR|| ||
+|Polycythemia Vera (PV)
+|Gokce A. Toruner, MD, PhD  UT MD Anderson Cancer Center
+|Complete
+|
+|
 |-
-|Essential thrombocythaemia||Disease||Rebecca Smith, PhD, Director, Genetics Associates, Nashville, TN|| || || || ||FQR||
+|[[HAEM5:Essential thrombocythaemia|Essential thrombocythaemia]]||Disease||PENDING
-| ||
+| || || || ||FQR|| ||
+|Essential Thrombocythemia (ET)
+|Rebecca Smith, PhD, Director, Genetics Associates, Nashville, TN
+|Complete
+|
+|
 |-
-|Primary myelofibrosis||Disease||T. Niroshi Senaratne, UCLA|| || || || ||FQR||
+|[[HAEM5:Primary myelofibrosis|Primary myelofibrosis]]||Disease||PENDING
-| ||
+| || || || ||FQR|| ||
+|Primary Myelofibrosis (PMF)
+|T. Niroshi Senaratne, UCLA
+|Complete
+|8/4/2020 before submission<br />
+|
 |-
-|Juvenile myelomonocytic leukaemia||Disease|| '''Sarah Rapisardo, PhD, FACMG''' |Assistant Professor, Pathology  Associate Director | Division of Molecular Pathology, Genetics and Genomics  Duke University Health System Clinical Laboratories|| || || || ||FQR||
+|[[HAEM5:Juvenile myelomonocytic leukaemia|Juvenile myelomonocytic leukaemia]]||Disease|| '''Sarah Rapisardo, PhD, FACMG''' |PENDING
-| ||
+| || || || ||FQR|| ||
+|Juvenile Myelomonocytic Leukemia (JMML)
+|<nowiki>Sarah Rapisardo, PhD, FACMG | Assistant Professor, Pathology</nowiki>
+Associate Director | Division of Molecular Pathology, Genetics and Genomics
+Duke University Health System Clinical Laboratories
+|PENDING importing content and reference formatting
+|
+|FQR has emailed SR several times, last 4/20/22
 |-
-|Myeloproliferative neoplasm, NOS||Disease||Thomas Lee, MD, PhD, University of California, Los Angeles|| || || || ||FQR||
+|[[HAEM5:Myeloproliferative neoplasm, NOS|Myeloproliferative neoplasm, NOS]]||Disease||PENDING
-| ||
+| || || || ||FQR|| ||
+|Myeloproliferative Neoplasm (MPN), Unclassifiable
+|Thomas Lee, MD, PhD, University of California, Los Angeles
+|Complete
+|
+|
 |-
-|Cutaneous mastocytosis||Disease||S. Shawn Liu, MD, PhD and Thuy Phung, MD, PhD|| || || || ||FQR||
+|[[HAEM5:Cutaneous mastocytosis|Cutaneous mastocytosis]]||Disease||PENDING
-| ||
+| || || || ||FQR|| ||
+|Cutaneous Mastocytosis
+|S. Shawn Liu, MD, PhD and Thuy Phung, MD, PhD
+|Complete
+|
+|
 |-
-|Systemic mastocytosis||Disease||'''Abdullah Osme, MD,''' University Hospitals Cleveland Medical Center, Case Western Reserve University  '''Shashi Shetty, Ph.D. FACMG, FCCMG,''' University Hospitals Cleveland Medical Center, Case Western Reserve University|| || || || ||FQR||
+|[[HAEM5:Systemic mastocytosis|Systemic mastocytosis]]||Disease||PENDING|| || || || ||FQR|| ||
-| ||
+|Systemic Mastocytosis
+|Abdullah Osme, MD, University Hospitals Cleveland Medical Center, Case Western Reserve University  Shashi Shetty, Ph.D. FACMG, FCCMG, University Hospitals Cleveland Medical Center, Case Western Reserve University
+|Complete
+|
+|
 |-
-|Mast cell sarcoma||Disease||Jordan Lowery, MD and Thuy Phung, MD, PhD   Department of Pathology, University of South Alabama, Mobile, AL|| || || || ||FQR||
+|[[HAEM5:Mast cell sarcoma|Mast cell sarcoma]]||Disease||PENDING
-| ||
+| || || || ||FQR|| ||
+|Mast Cell Sarcoma
+|Jordan Lowery, MD and Thuy Phung, MD, PhD   Department of Pathology, University of South Alabama, Mobile, AL
+|Complete
+|
+|
 |-
-|Myelodysplastic neoplasm with low blasts and 5q deletion||Disease|| || || || || ||FQR||
+|[[HAEM5:Myelodysplastic neoplasm with low blasts and 5q deletion|Myelodysplastic neoplasm with low blasts and 5q deletion]]||Disease||PENDING
-| ||
+| || || || ||FQR|| ||
+|Myelodysplastic Syndrome (MDS) with Isolated del(5q)
+|Xiaolin Hu, Ph.D; Teresa Smolarek, Ph.D, FACMG
+|Complete
+|
+|
 |-
-|Myelodysplastic neoplasm with low blasts and SF3B1 mutation||Disease|| || || || || ||FQR||
+|[[HAEM5:Myelodysplastic neoplasm with low blasts and SF3B1 mutation|Myelodysplastic neoplasm with low blasts and SF3B1 mutation]]||Disease||PENDING
-| ||
+| || || || ||FQR|| ||
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
 |-
-|Myelodysplastic neoplasm with biallelic TP53 inactivation||Disease|| || || || || ||FQR||
+|[[HAEM5:Myelodysplastic neoplasm with biallelic TP53 inactivation|Myelodysplastic neoplasm with biallelic TP53 inactivation]]||Disease||Eric McGinnis (assigned to new 5th edition page - FQR is this reviewed?)|| || || || ||FQR|| ||
-| ||
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
 |-
-|Myelodysplastic neoplasm with low blasts||Disease|| || || || || ||FQR||
+|[[HAEM5:Myelodysplastic neoplasm with low blasts|Myelodysplastic neoplasm with low blasts]]||Disease|| || || || || ||FQR|| ||
-| ||
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
 |-
-|Myelodysplastic neoplasm, hypoplastic||Disease|| || || || || ||FQR||
+|[[HAEM5:Myelodysplastic neoplasm, hypoplastic|Myelodysplastic neoplasm, hypoplastic]]||Disease|| || || || || ||FQR|| ||
-| ||
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
 |-
-|Myelodysplastic neoplasm with increased blasts||Disease||Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG  Division of Human Genetics, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH, 45229, USA.|| || || || ||FQR||
+|[[HAEM5:Myelodysplastic neoplasm with increased blasts|Myelodysplastic neoplasm with increased blasts]]||Disease||PENDING
-| ||
+| || || || ||FQR|| ||
+|Myelodysplastic Syndrome (MDS) with Excess Blasts
+|Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG  Division of Human Genetics, Cincinnati Children's Hospital Medical Center
+|Complete
+|
+|
 |-
-|Childhood myelodysplastic neoplasm with low blasts||Disease||Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG  Division of Human Genetics, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH, 45229, USA.|| || || || ||FQR||
+|[[HAEM5:Childhood myelodysplastic neoplasm with low blasts|Childhood myelodysplastic neoplasm with low blasts]]||Disease||PENDING
-| ||
+| || || || ||FQR|| ||
+|Refractory Cytopenia of Childhood
+|Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG  Division of Human Genetics, Cincinnati Children's Hospital Medical Center
+|Complete
+|
+|
 |-
-|Childhood myelodysplastic neoplasm with increased blasts||Disease||Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG  Division of Human Genetics, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH, 45229, USA.|| || || || ||FQR||
+|[[HAEM5:Childhood myelodysplastic neoplasm with increased blasts|Childhood myelodysplastic neoplasm with increased blasts]]||Disease||PENDING
-| ||
+| || || || ||FQR|| ||
+|Refractory Cytopenia of Childhood
+|Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG  Division of Human Genetics, Cincinnati Children's Hospital Medical Center
+|Complete
+|
+|
 |-
-|Chronic myelomonocytic leukaemia||Disease||Linsheng Zhang, MD, PhD|| || || || ||FQR||
+|[[HAEM5:Chronic myelomonocytic leukaemia|Chronic myelomonocytic leukaemia]]||Disease||PENDING
-| ||
+| || || || ||FQR|| ||
+|Chronic Myelomonocytic Leukemia (CMML)
+|Linsheng Zhang, MD, PhD
+|Complete
+|
+|
 |-
-|Myelodysplastic/myeloproliferative neoplasm with neutrophilia||Disease||Linsheng Zhang, MD, PhD|| || || || ||FQR||
+|[[HAEM5:Myelodysplastic/myeloproliferative neoplasm with neutrophilia|Myelodysplastic/myeloproliferative neoplasm with neutrophilia]]||Disease||PENDING
-| ||
+| || || || ||FQR|| ||
+|Atypical Chronic Myeloid Leukemia (aCML), BCR-ABL1 Negative
+|Linsheng Zhang, MD, PhD
+|Complete
+|
+|
 |-
-|Myelodysplastic/myeloproliferative neoplasm with SF3B1 mutation and thrombocytosis||Disease||Anamaria Munteanu, MD, Ph.D, Harbor-UCLA Medical Center, Fabiola Quintero-Rivera, University of California Irvine|| || || || ||FQR||
+|[[HAEM5:Myelodysplastic/myeloproliferative neoplasm with SF3B1 mutation and thrombocytosis|Myelodysplastic/myeloproliferative neoplasm with SF3B1 mutation and thrombocytosis]]||Disease||PENDING
-| ||
+| || || || ||FQR|| ||
+|Myelodysplastic/Myeloproliferative Neoplasms with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T)
+|Anamaria Munteanu, MD, Ph.D, Harbor-UCLA Medical Center, Fabiola Quintero-Rivera, University of California Irvine
+|Complete
+|Date page was created
+|
 |-
-|Myelodysplastic/myeloproliferative neoplasm, NOS||Disease||Ruth MacKinnon PhD  Victorian Cancer Cytogenetics Service  Melbourne, Australia|| || || || ||FQR||
+|[[HAEM5:Myelodysplastic/myeloproliferative neoplasm, NOS|Myelodysplastic/myeloproliferative neoplasm, NOS]]||Disease||PENDING
-| ||
+| || || || ||FQR|| ||
+|Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN), Unclassifiable
+|Ruth MacKinnon PhD  Victorian Cancer Cytogenetics Service  Melbourne, Australia
+|Complete
+|
+|
 |-
-|Myeloid/lymphoid neoplasm with PDGFRA rearrangement||Disease||Jay Alden, DO|| || || || ||FQR||
+|[[HAEM5:Acute promyelocytic leukaemia with PML::RARA fusion|Acute promyelocytic leukaemia with PML::RARA fusion]]
-| ||
+|Disease
-|-
+|PENDING
-|Myeloid/lymphoid neoplasm with PDGFRB rearrangement||Disease||Christopher Sullivan, MD, MPH and Daynna J. Wolff, PhD|| || || || ||FQR||
+|
-| ||
+|
-|-
+|
-|Myeloid/lymphoid neoplasm with FGFR1 rearrangement||Disease||Yanna Ding, MD PhD|| || || || ||FQR||
+|
-| ||
+|Jennelle Hodge (JH)/ Malini Sathanoori (MS)
-|-
+|
-|Myeloid/lymphoid neoplasm with JAK2 rearrangement||Disease||Jessica Snider, M.D. and Daynna J. Wolff, PhD|| || || || ||FQR||
+|
-| ||
+|Acute Promyelocytic Leukemia (APL) with PML-RARA
-|-
+|Yiming Zhong, Ph.D., Megan Piazza, Ph.D., and Shashi Shetty, Ph.D.
-|Myeloid/lymphoid neoplasm with FLT3 rearrangement||Disease|| || || || || ||FQR||
+|Complete
-| ||
+|03/01/2021-MS (re-review)
-|-
+|
-|Myeloid/lymphoid neoplasm with ETV6::ABL1 fusion||Disease|| || || || || ||FQR||
-| ||
-|-
-|Myeloid/lymphoid neoplasms with other tyrosine kinase fusion genes||Disease|| || || || || ||FQR||
-| ||
 |-
+|[[HAEM5:Acute myeloid leukaemia with RUNX1::RUNX1T1 fusion|Acute myeloid leukaemia with RUNX1::RUNX1T1 fusion]]
+|Disease
+|PENDING
+|
+|
+|
 |
+|JH_MS
 |
 |
+|Acute Myeloid Leukemia (AML) with t(8;21)(q22;q22.1); RUNX1-RUNX1T1
+|Christine Bryke, MD<br>Beth Israel Deaconess Medical Center, Boston, MA
+|Complete
+|04/26/2021-MS (re-review)
 |
+|-
+|[[HAEM5:Acute myeloid leukaemia with CBFB::MYH11 fusion|Acute myeloid leukaemia with CBFB::MYH11 fusion]]
+|Disease
+|PENDING
 |
 |
 |
 |
+|JH_MS
 |
 |
+|Acute Myeloid Leukemia (AML) with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11
+|Christine Bryke, MD <br> Beth Israel Deaconess Medical Center, Boston, MA
+|Complete
+|03/01/2021-MS (re-review)
 |
 |-
-|Acute promyelocytic leukaemia with PML::RARA fusion
+|[[HAEM5:Acute myeloid leukaemia with DEK::NUP214 fusion|Acute myeloid leukaemia with DEK::NUP214 fusion]]
 |Disease
-|Yiming Zhong, Ph.D., Megan Piazza, Ph.D., and Shashi Shetty, Ph.D.
+|PENDING
 |
 |
 |
 |
-|Jennelle Hodge (JH)/ Malini Sathanoori (MS)
+|JH_MS
 |
 |
+|Acute Myeloid Leukemia (AML) with t(6;9)(p23;q34.1); DEK-NUP214
+|Jennelle C. Hodge, PhD, FACMG
+|Complete
+|02/24/2021-MS (re-review)
 |
 |-
-|Acute myeloid leukaemia with RUNX1::RUNX1T1 fusion
+|[[HAEM5:Acute myeloid leukaemia with RBM15::MRTFA fusion|Acute myeloid leukaemia with RBM15::MRTFA fusion]]
 |Disease
-|Christine Bryke, MD<br>Beth Israel Deaconess Medical Center, Boston, MA
+|PENDING
 |
 |
@@ Line 148: / Line 325: @@
 |JH_MS
 |
+|
+|Acute Myeloid Leukemia (AML) Megakaryoblastic with t(1;22)(p13.3;q13.1);RBM15-MKL1
+|Jennelle C. Hodge, PhD, FACMG
+|Complete
 |
 |
 |-
-|Acute myeloid leukaemia with CBFB::MYH11 fusion
+|[[HAEM5:Acute myeloid leukaemia with BCR::ABL1 fusion|Acute myeloid leukaemia with BCR::ABL1 fusion]]
 |Disease
-|Christine Bryke, MD <br> Beth Israel Deaconess Medical Center, Boston, MA
+|PENDING
 |
 |
@@ Line 160: / Line 341: @@
 |JH_MS
 |
+|
+|Acute Myeloid Leukemia (AML) with BCR-ABL1
+|Kay Weng Choy MBBS, Monash Medical Centre
+|Complete
 |
 |
 |-
-|Acute myeloid leukaemia with DEK::NUP214 fusion
+|[[HAEM5:Acute myeloid leukaemia with KMT2A rearrangement|Acute myeloid leukaemia with KMT2A rearrangement]]
 |Disease
-|
+|PENDING
 |
 |
@@ Line 173: / Line 358: @@
 |
 |
+|Acute Myeloid Leukemia (AML) with t(9;11)(p21.3;q23.3); KMT2A-MLLT3
+|Megan Piazza, Ph.D., Yiming Zhong, Ph.D., Shashi Shetty, Ph.D.
+|Complete
+|03/01/2021-MS (re-review)
 |
 |-
-|Acute myeloid leukaemia with RBM15::MRTFA fusion
+|[[HAEM5:Acute myeloid leukaemia with MECOM rearrangement|Acute myeloid leukaemia with MECOM rearrangement]]
 |Disease
-|Jennelle C. Hodge, PhD, FACMG
+|PENDING
 |
 |
@@ Line 184: / Line 373: @@
 |JH_MS
 |
+|
+|Acute Myeloid Leukemia (AML) with inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2);GATA2, MECOM
+|Gordana Raca MD PhD, University of Southern California, Los Angeles
+|Complete
+|
+|Need permission for figure? Update WHO?
+|-
+|[[HAEM5:Acute myeloid leukaemia with NUP98 rearrangement|Acute myeloid leukaemia with NUP98 rearrangement]]
+|Disease
+|Eric McGinnis, MD
+|12/20/23
+|
+|
+|
+|JH_MS
 |
 |
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
 |-
-|Acute myeloid leukaemia with BCR::ABL1 fusion
+|[[HAEM5:Acute myeloid leukaemia with NPM1 mutation|Acute myeloid leukaemia with NPM1 mutation]]
 |Disease
-|Kay Weng Choy MBBS, Monash Medical Centre
+|PENDING
 |
 |
@@ Line 197: / Line 406: @@
 |
 |
+|Acute Myeloid Leukemia (AML) with Mutated NPM1
+|Xinjie Xu, PhD, FACMG
+|Complete
 |
+|Add WHO reference
 |-
-|Acute myeloid leukaemia with KMT2A rearrangement
+|[[HAEM5:Acute myeloid leukaemia with CEBPA mutation|Acute myeloid leukaemia with CEBPA mutation]]
 |Disease
-|Megan Piazza, Ph.D., Yiming Zhong, Ph.D., Shashi Shetty, Ph.D.
+|PENDING
 |
 |
@@ Line 208: / Line 421: @@
 |JH_MS
 |
+|
+|Acute Myeloid Leukemia (AML) with Biallelic Mutations of CEBPA
+|Paul Defazio, MSc, Monash Health
+|Complete
 |
 |
 |-
-|Acute myeloid leukaemia with MECOM rearrangement
+|[[HAEM5:Acute myeloid leukaemia, myelodysplasia-related|Acute myeloid leukaemia, myelodysplasia-related]]
 |Disease
+|PENDING
 |
 |
 |
 |
+|JH_MS
 |
-|JH_MS
 |
+|Acute Myeloid Leukemia (AML) with Myelodysplasia-Related Changes
+|Fei Yang, MD, FACMG  <br> Oregon Health & Science University
+|Complete
 |
 |
 |-
-|Acute myeloid leukaemia with NUP98 rearrangement
+|[[HAEM5:Acute myeloid leukaemia with other defined genetic alterations|Acute myeloid leukaemia with other defined genetic alterations]]
 |Disease
 |
@@ Line 233: / Line 454: @@
 |
 |
-|
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
 |-
-|Acute myeloid leukaemia with NPM1 mutation
+|[[HAEM5:Acute myeloid leukaemia with minimal differentiation|Acute myeloid leukaemia with minimal differentiation]]
 |Disease
-|Xinjie Xu, PhD, FACMG
+|PENDING
 |
 |
@@ Line 244: / Line 469: @@
 |JH_MS
 |
+|
+|Acute Myeloid Leukemia (AML) with Minimal Differentiation
+|Celeste Eno, PhD, Cedars Sinai Medical Center, Los Angeles,  Fabiola Quintero-Rivera, MD, FACMG, University of California Irvine
+|Complete
 |
 |
 |-
-|Acute myeloid leukaemia with CEBPA mutation
+|[[HAEM5:Acute myeloid leukaemia without maturation|Acute myeloid leukaemia without maturation]]
 |Disease
-|Paul Defazio, MSc, Monash Health
+|PENDING
 |
 |
@@ Line 256: / Line 485: @@
 |JH_MS
 |
+|
+|Acute Myeloid Leukemia (AML) without Maturation
+|Jennelle C. Hodge, PhD, FACMG
+|Complete
 |
 |
 |-
-|Acute myeloid leukaemia, myelodysplasia-related
+|[[HAEM5:Acute myeloid leukaemia with maturation|Acute myeloid leukaemia with maturation]]
 |Disease
-|Fei Yang, MD, FACMG  <br> Oregon Health & Science University, Portland, OR
+|PENDING
 |
 |
@@ Line 268: / Line 501: @@
 |JH_MS
 |
+|
+|Acute Myeloid Leukemia (AML) with Maturation
+|Jennelle C. Hodge, PhD, FACMG
+|Complete
 |
 |
 |-
-|Acute myeloid leukaemia with other defined genetic alterations
+|[[HAEM5:Acute basophilic leukaemia|Acute basophilic leukaemia]]
 |Disease
-|
+|PENDING
 |
 |
@@ Line 280: / Line 517: @@
 |JH_MS
 |
+|
+|Acute Basophilic Leukemia
+|Ashwini Yenamandra PhD FACMG
+|Complete
 |
 |
 |-
-|Acute myeloid leukaemia with minimal differentiation
+|[[HAEM5:Acute myelomonocytic leukaemia|Acute myelomonocytic leukaemia]]
 |Disease
-|Celeste Eno, PhD, Cedars Sinai Medical Center, Los Angeles,  Fabiola Quintero-Rivera, MD, FACMG, University of California Irvine
+|PENDING
 |
 |
@@ Line 292: / Line 533: @@
 |JH_MS
 |
+|
+|Acute Myelomonocytic Leukemia
+|Fei Yang, MD, FACMG <br> Oregon Health & Science University
+|Complete
 |
 |
 |-
-|Acute myeloid leukaemia without maturation
+|[[HAEM5:Acute monocytic leukaemia|Acute monocytic leukaemia]]
 |Disease
-|Jennelle C. Hodge, PhD, FACMG
+|PENDING
 |
 |
@@ Line 304: / Line 549: @@
 |JH_MS
 |
+|
+|Acute Monoblastic and Monocytic Leukemia
+|Fei Yang, MD, FACMG <br> Oregon Health & Science University
+|Complete
 |
 |
 |-
-|Acute myeloid leukaemia with maturation
+|[[HAEM5:Acute erythroid leukaemia|Acute erythroid leukaemia]]
 |Disease
-|Jennelle C. Hodge, PhD, FACMG
+|PENDING
 |
 |
@@ Line 316: / Line 565: @@
 |JH_MS
 |
+|
+|Pure Erythroid Leukemia
+|Ashwini Yenamandra PhD FACMG
+|Complete
 |
 |
 |-
-|Acute basophilic leukaemia
+|[[HAEM5:Acute megakaryoblastic leukaemia|Acute megakaryoblastic leukaemia]]
 |Disease
-|Ashwini Yenamandra PhD FACMG
+|PENDING
 |
 |
@@ Line 328: / Line 581: @@
 |JH_MS
 |
+|
+|Acute Megakaryoblastic Leukemia (AMKL)
+|Fei Yang, MD, FACMG <br> Oregon Health & Science University
+|Complete
 |
 |
 |-
-|Acute myelomonocytic leukaemia
+|[[HAEM5:Myeloid sarcoma|Myeloid sarcoma]]
 |Disease
-|Fei Yang, MD, FACMG <br> Oregon Health & Science University, Portland, OR
+|PENDING
 |
 |
@@ Line 339: / Line 596: @@
 |
 |JH_MS
+|
+|
+|Myeloid Sarcoma
+|Yalda Naeini, MD, School of Medicine at University of California Los Angeles Fabiola Quintero-Rivera, MD, FACMG, School of Medicine at University of California Irvine
+|Complete
+|
+|
+|-
+|RESOLVE 4th edition AML-Related NON-WHO entities content
+|[[HAEM4:Acute Myeloid Leukemia (AML) with Mutated FLT3|Acute Myeloid Leukemia (AML) with Mutated FLT3]] + [[HAEM4:Acute Myeloid Leukemia (AML) with NUP214-ABL1|Acute Myeloid Leukemia (AML) with NUP214-ABL1]] + [[HAEM4:Acute Myeloid Leukemia (AML) with t(4;12)(q12;p13); CHIC2-ETV6|Acute Myeloid Leukemia (AML) with t(4;12)(q12;p13); CHIC2-ETV6]]
+|ISSUE- FIX
+Resolve Non-WHO entities
+|
+|
+|
+|
+|
+|
+|
+|
+|
 |
 |
 |
 |-
-|Acute monocytic leukaemia
+|[[HAEM5:Myeloid neoplasm post cytotoxic therapy|Myeloid neoplasm post cytotoxic therapy]]
 |Disease
-|Fei Yang, MD, FACMG  <br> Oregon Health & Science University, Portland, OR
+|PENDING
 |
 |
@@ Line 353: / Line 633: @@
 |
 |
+|Therapy-Related Myeloid Neoplasms
+|Shawn A. Silver, DO, Shashi Shetty, Ph.D.
+|Complete
 |
+|Check reference format
 |-
-|Acute erythroid leukaemia
+|[[HAEM5:Myeloid neoplasms associated with germline predisposition|Myeloid neoplasms associated with germline predisposition]]
 |Disease
-|Ashwini Yenamandra PhD FACMG
+|PENDING
 |
 |
@@ Line 365: / Line 649: @@
 |
 |
-|
+|Multiple pages including overview page ([[Myeloid Neoplasms with Germline Predisposition|Myeloid Neoplasms with Germline Predisposition - Compendium of Cancer Genome Aberrations (ccga.io)]]) and 6 disease pages ( [[HAEM4:Acute Myeloid Leukaemia with Germline CEBPA Mutation]], [[HAEM4:Myeloid Neoplasms with Germline DDX41 Mutation]], [[HAEM4:Myeloid Neoplasms with Germline ETV6 Mutation]], [[HAEM4:Myeloid Neoplasms with Germline GATA2 Mutation]], [[HAEM4:Myeloid Neoplasms with Germline RUNX1 Mutation]], [[HAEM4:Myeloid Neoplasms with Germline ANKRD26 Mutation]])
+|See links from instructions on the 5th edition page
+|Complete
+|Most were re-reviewed by MS on 03/02/2021
+|For page Acute Myeloid Leukaemia with Germline CEBPA Mutation - Note by MS of "Review completed, awaiting some clarification from JH - 07/04/2022"
 |-
-|Acute megakaryoblastic leukaemia
+|[[HAEM5:Myeloid proliferations associated with Down syndrome|Myeloid proliferations associated with Down syndrome]]
 |Disease
-|Fei Yang, MD, FACMG  <br> Oregon Health & Science University, Portland, OR
+|PENDING
 |
 |
@@ Line 376: / Line 664: @@
 |JH_MS
 |
+|
+|MERGE 3 PAGES --> Transient Abnormal Myelopoiesis (TAM) Associated with Down Syndrome  +  Transient Abnormal Myelopoiesis (TAM) Associated with Down Syndrome + Myeloid Leukemia Associated with Down Syndrome
+|Linda D Cooley, MD, MBA, Children's Mercy Hospital, Kansas City, MO
+|Complete (all three pages)
 |
 |
 |-
-|Myeloid sarcoma
+|[[HAEM5:Myeloid/lymphoid neoplasm with PDGFRA rearrangement|Myeloid/lymphoid neoplasm with PDGFRA rearrangement]]
 |Disease
-|Yalda Naeini, MD, School of Medicine at University of California Los Angeles Fabiola Quintero-Rivera, MD, FACMG, School of Medicine at University of California Irvine
+|PENDING
+|
 |
 |
 |
+|FQR
 |
-|JH_MS
 |
+|Myeloid/Lymphoid Neoplasms with PDGFRA Rearrangement
+|Jay Alden, DO
+|Complete
 |
 |
 |-
-|Myeloid neoplasm post cytotoxic therapy
+|[[HAEM5:Myeloid/lymphoid neoplasm with PDGFRB rearrangement|Myeloid/lymphoid neoplasm with PDGFRB rearrangement]]
 |Disease
-|Shawn A. Silver, DO, Shashi Shetty, Ph.D.
+|PENDING
+|
 |
 |
 |
+|FQR
 |
-|JH_MS
 |
+|Myeloid/Lymphoid Neoplasms with PDGFRB Rearrangement
+|Christopher Sullivan, MD, MPH and Daynna J. Wolff, PhD
+|Complete
 |
 |
 |-
-|Myeloid neoplasms associated with germline predisposition
+|[[HAEM5:Myeloid/lymphoid neoplasm with FGFR1 rearrangement|Myeloid/lymphoid neoplasm with FGFR1 rearrangement]]
 |Disease
+|PENDING
 |
 |
 |
 |
+|FQR
 |
-|JH_MS
 |
+|Myeloid/Lymphoid Neoplasms with FGFR1 Rearrangement
+|Yanna Ding, MD PhD
+|Complete
 |
 |
 |-
-|Myeloid proliferations associated with Down syndrome
+|[[HAEM5:Myeloid/lymphoid neoplasm with JAK2 rearrangement|Myeloid/lymphoid neoplasm with JAK2 rearrangement]]
 |Disease
-|Linda D Cooley, MD, MBA, Children's Mercy Hospital, Kansas City, MO
+|ISSUE- FIX
+Resolve Non-WHO entities
+|
 |
 |
 |
+|FQR
 |
-|JH_MS
 |
+|Myeloid/Lymphoid Neoplasms with PCM1-JAK2 + consider a non-WHO page Myeloid/Lymphoid Neoplasms with ETV6-JAK2 ([[HAEM4:Myeloid/Lymphoid Neoplasms with ETV6-JAK2|Myeloid/Lymphoid Neoplasms with ETV6-JAK2 - Compendium of Cancer Genome Aberrations (ccga.io)]])  + another non-WHO page Myeloid/Lymphoid Neoplasms with BCR-JAK2 ([[HAEM4:Myeloid/Lymphoid Neoplasms with BCR-JAK2|Myeloid/Lymphoid Neoplasms with BCR-JAK2 - Compendium of Cancer Genome Aberrations (ccga.io)]] )  - both non-WHO pages are authored by trainee Lauren Crowson-Hindman and Daynna Wolff
+|Jessica Snider, M.D. and Daynna J. Wolff, PhD + non-WHO pages by trainee Lauren Crowson-Hindman and Daynna Wolff
+|Complete
 |
 |
 |-
-|Mixed-phenotype acute leukaemia with BCR::ABL1 fusion
+|[[HAEM5:Myeloid/lymphoid neoplasm with FLT3 rearrangement|Myeloid/lymphoid neoplasm with FLT3 rearrangement]]
 |Disease
-|Tracy Tucker, PhD, FCCMG
 |
 |
 |
 |
-|JH_MS
 |
+|FQR
 |
 |
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
 |-
-|Mixed-phenotype acute leukaemia with KMT2A rearrangement
+|[[HAEM5:Myeloid/lymphoid neoplasm with ETV6::ABL1 fusion|Myeloid/lymphoid neoplasm with ETV6::ABL1 fusion]]
 |Disease
-|Tracy Tucker, PhD, FCCMG
 |
 |
 |
 |
-|JH_MS
 |
+|FQR
 |
 |
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
 |-
-|Acute leukaemia of ambiguous lineage with other defined genetic alterations
+|[[HAEM5:Myeloid/lymphoid neoplasms with other tyrosine kinase fusion genes|Myeloid/lymphoid neoplasms with other tyrosine kinase fusion genes]]
 |Disease
 |
@@ Line 457: / Line 776: @@
 |
 |
+|
+|FQR
+|
+|
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
+|-
+|[[HAEM5:Mixed-phenotype acute leukaemia with BCR::ABL1 fusion|Mixed-phenotype acute leukaemia with BCR::ABL1 fusion]]
+|Disease
+|Tracy Tucker, PhD, FCCMG
+|4/6/24
+|
+|Pending
 |
 |JH_MS
 |
+|
+|Mixed Phenotype Acute Leukemia (MPAL) with t(9;22)(q34.1;q11.2); BCR-ABL1
+|Tracy Tucker, PhD, FCCMG
+|Complete
 |
 |
 |-
-|Mixed-phenotype acute leukaemia, B/myeloid
+|[[HAEM5:Mixed-phenotype acute leukaemia with KMT2A rearrangement|Mixed-phenotype acute leukaemia with KMT2A rearrangement]]
 |Disease
-|Priyatharsini Nirmalanantham, MD and  Shashi Shetty, PhD
+|Tracy Tucker, PhD, FCCMG
+|4/6/24
 |
+|Pending
 |
+|JH_MS
 |
 |
-|JH_MS
+|Mixed Phenotype Acute Leukemia (MPAL) with t(v;11q23.3); KMT2A Rearranged
-|
+|Tracy Tucker, PhD, FCCMG
+|Complete
 |
 |
 |-
-|Mixed-phenotype acute leukaemia, T/myeloid
+|[[HAEM5:Acute leukaemia of ambiguous lineage with other defined genetic alterations|Acute leukaemia of ambiguous lineage with other defined genetic alterations]]
 |Disease
-|Narsis Attar, MD, PhD, Fabiola Quintero-Rivera, MD University of California, Irvine
+|
 |
 |
@@ Line 485: / Line 828: @@
 |
 |
-|
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
 |-
-|Mixed-phenotype acute leukaemia, rare types
+|[[HAEM5:Mixed-phenotype acute leukaemia, B/myeloid|Mixed-phenotype acute leukaemia, B/myeloid]]
 |Disease
-|Elicia Goodale, MD, Medical University of South Carolina  Daynna Wolff, PhD, Medical University of South Carolina
+|PENDING
 |
 |
@@ Line 496: / Line 843: @@
 |JH_MS
 |
+|
+|Mixed Phenotype Acute Leukemia (MPAL), B/Myeloid, Not Otherwise Specified
+|Priyatharsini Nirmalanantham, MD and  Shashi Shetty, PhD
+|Complete
 |
 |
 |-
-|Acute leukaemia of ambiguous lineage, NOS
+|[[HAEM5:Mixed-phenotype acute leukaemia, T/myeloid|Mixed-phenotype acute leukaemia, T/myeloid]]
 |Disease
-|
+|PENDING
 |
 |
@@ Line 508: / Line 859: @@
 |JH_MS
 |
+|
+|Mixed Phenotype Acute Leukemia (MPAL), T/Myeloid, Not Otherwise Specified
+|Narsis Attar, MD, PhD, Fabiola Quintero-Rivera, MD University of California, Irvine
+|Complete
 |
 |
 |-
-|Acute undifferentiated leukaemia
+|[[HAEM5:Mixed-phenotype acute leukaemia, rare types|Mixed-phenotype acute leukaemia, rare types]]
 |Disease
-|Amelia Nakanishi, MD and Shashi Shetty, PhD
+|PENDING
 |
 |
@@ Line 520: / Line 875: @@
 |JH_MS
 |
+|
+|Mixed-Phenotype Acute Leukemia, Not Otherwise Specified (NOS), Rare Types
+|Elicia Goodale, MD, Medical University of South Carolina  Daynna Wolff, PhD, Medical University of South Carolina
+|PENDING
 |
 |
 |-
+|[[HAEM5:Acute leukaemia of ambiguous lineage, NOS|Acute leukaemia of ambiguous lineage, NOS]]
+|Disease
 |
 |
@@ Line 528: / Line 889: @@
 |
 |
+|JH_MS
 |
 |
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
+|-
+|[[HAEM5:Acute undifferentiated leukaemia|Acute undifferentiated leukaemia]]
+|Disease
+|PENDING
 |
 |
 |
 |
+|JH_MS
+|
+|
+|Acute Undifferentiated Leukemia
+|Amelia Nakanishi, MD and Shashi Shetty, PhD
+|Complete
+|
+|Check reference format
 |-
 |CHAPTER 3 (HISTIOCYTIC/DENRITIC CELL NEOPLASMS)
@@ Line 541: / Line 920: @@
 ----<br />
 |
+----<br />
+|
+----<br />
+|
+----<br />
 |
+----<br />
 |
+----<br />
 |
+----<br />
 |
+----<br />
 |
+----<br />
 |
+----<br />
 |
+----<br />
+|
+----<br />
+|
+----<br />
 |-
-|Mature plasmacytoid dendritic cell proliferation associated with myeloid neoplasm
+|[[HAEM5:Mature plasmacytoid dendritic cell proliferation associated with myeloid neoplasm|Mature plasmacytoid dendritic cell proliferation associated with myeloid neoplasm]]
 |Disease
 |
@@ Line 559: / Line 954: @@
 |
 |
-|
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
 |-
-|Blastic plasmacytoid dendritic cell neoplasm
+|[[HAEM5:Blastic plasmacytoid dendritic cell neoplasm|Blastic plasmacytoid dendritic cell neoplasm]]
 |Disease
-|Hao Liu, MD and Daynna J. Wolff, PhD
+|PENDING
 |
 |
@@ Line 571: / Line 970: @@
 |
 |
+|Blastic Plasmacytoid Dendritic Cell Neoplasm
+|Hao Liu, MD and Daynna J. Wolff, PhD
+|Complete
 |
+|Previously within myeloid section under JH/MS editors
 |-
-|Langerhans cell histiocytosis
+|[[HAEM5:Langerhans cell histiocytosis|Langerhans cell histiocytosis]]
 |Disease
-|Dr Malaika Perchard BSci(MedSci), MBBS, FRACP, FRCPA, (Paediatric Haematologist) Pathology Queensland
+|PENDING
 |
 |
@@ Line 583: / Line 986: @@
 |
 |
-|
+|Langerhans Cell Histiocytosis
+|Dr Malaika Perchard BSci(MedSci), MBBS, FRACP, FRCPA, (Paediatric Haematologist) Pathology Queensland
+|Complete
+|5/19/2022<br />
+|Date completed by author: 04/28/2022
 |-
-|Langerhans cell sarcoma
+|[[HAEM5:Langerhans cell sarcoma|Langerhans cell sarcoma]]
 |Disease
-|Dr Malaika Perchard BSci(MedSci), MBBS, FRACP, FRCPA, (Paediatric Haematologist) Pathology Queensland
+|PENDING
 |
 |
@@ Line 595: / Line 1,002: @@
 |
 |
-|
+|Langerhans Cell Sarcoma
+|Dr Malaika Perchard BSci(MedSci), MBBS, FRACP, FRCPA, (Paediatric Haematologist) Pathology Queensland
+|Complete
+|5/19/2022<br />
+|Date completed by author: 04/28/2022
 |-
-|Indeterminate dendritic cell tumour
+|[[HAEM5:Indeterminate dendritic cell tumour|Indeterminate dendritic cell tumour]]
 |Disease
 |
@@ Line 607: / Line 1,018: @@
 |
 |
-|
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
 |-
-|Interdigitating dendritic cell sarcoma
+|[[HAEM5:Interdigitating dendritic cell sarcoma|Interdigitating dendritic cell sarcoma]]
 |Disease
 |
@@ Line 619: / Line 1,034: @@
 |
 |
-|
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
 |-
-|Juvenile xanthogranuloma
+|[[HAEM5:Juvenile xanthogranuloma|Juvenile xanthogranuloma]]
 |Disease
 |
@@ Line 631: / Line 1,050: @@
 |
 |
-|
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
 |-
-|Erdheim-Chester disease
+|[[HAEM5:Erdheim-Chester disease|Erdheim-Chester disease]]
 |Disease
 |
@@ Line 643: / Line 1,066: @@
 |
 |
-|
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
 |-
-|Rosai-Dorfman Disease
+|[[HAEM5:Rosai-Dorfman Disease|Rosai-Dorfman Disease]]
 |Disease
 |
@@ Line 655: / Line 1,082: @@
 |
 |
-|
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
 |-
-|ALK-positive histiocytosis
+|[[HAEM5:ALK-positive histiocytosis|ALK-positive histiocytosis]]
 |Disease
 |
@@ Line 667: / Line 1,098: @@
 |
 |
-|
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
 |-
-|Histiocytic sarcoma
+|[[HAEM5:Histiocytic sarcoma|Histiocytic sarcoma]]
 |Disease
-|Marie-France Gagnon, MD, Mayo Clinic, Xinjie Xu, PhD FACMG, Mayo Clinic
+|PENDING
 |
 |
@@ Line 679: / Line 1,114: @@
 |
 |
-|
+|Histiocytic Sarcoma
+|Marie-France Gagnon, MD, Mayo Clinic, Xinjie Xu, PhD FACMG, Mayo Clinic
+|Complete
+|10/01/2021
+|Date completed by author: 10/01/2021
 |-
+|CHAPTER 4 (B-CELL LYMPHOID PROLIFERATIONS AND LYMPHOMAS)
 |
+----<br />
 |
+----<br />
 |
+----<br />
 |
+----<br />
 |
+----<br />
 |
+----<br />
 |
+----<br />
 |
+----<br />
 |
+----<br />
 |
+----<br />
 |
-|-
+----<br />
-|CHAPTER 4 (B-CELL LYMPHOID PROLIFERATIONS AND LYMPHOMAS)
 |
 ----<br />
@@ Line 699: / Line 1,148: @@
 ----<br />
 |
+----<br />
+|-
+|[[HAEM5:Reactive B-cell rich lymphoid proliferations that can mimic lymphoma|Reactive B-cell rich lymphoid proliferations that can mimic lymphoma]]
+|Disease
 |
 |
@@ Line 704: / Line 1,157: @@
 |
 |
+|GC
 |
 |
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
 |-
-|CHAPTER 5 (T-CELL AND NK-CELL LYMPHOID PROLIFERATIONS AND LYMPHOMAS)
+|[[HAEM5:IgG4-related disease|IgG4-related disease]]
+|Disease
+|
+|
+|
+|
 |
-----<br />
+|GC
 |
-----<br />
 |
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
+|-
+|[[HAEM5:Unicentric Castleman disease|Unicentric Castleman disease]]
+|Disease
 |
 |
@@ Line 718: / Line 1,189: @@
 |
 |
+|GC
 |
 |
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
 |-
-|CHAPTER 6 (STROMA-DERIVED NEOPLASMS OF LYMPHOID TISSUES)
+|[[HAEM5:Idiopathic multicentric Castleman disease|Idiopathic multicentric Castleman disease]]
+|Disease
+|
 |
-----<br />
 |
-----<br />
 |
 |
+|GC
 |
 |
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
+|-
+|[[HAEM5:KSHV/HHV8-associated multicentric Castleman disease|KSHV/HHV8-associated multicentric Castleman disease]]
+|Disease
+|PENDING
 |
 |
 |
 |
+|GC
+|
+|
+|Multicentric Castleman Disease
+|Sudha Arumugam, MD
+|Complete
+|01/24/2022
+|Date completed by author: 01/24/2022
 |-
-|CHAPTER 7 (GENETIC TUMOUR SYNDROMES)
+|[[HAEM5:B-lymphoblastic leukaemia/lymphoma|B-lymphoblastic leukaemia/lymphoma]]
+|Disease
+|PENDING
+|
+|
+|
+|
+|Holli Drendel (HD)
+|
+|
+|B-Lymphoblastic Leukemia/Lymphoma, Not Otherwise Specified
+|Holli Drendel
+|PENDING
 |
-----<br />
 |
-----<br />
+|-
+|[[HAEM5:B-lymphoblastic leukaemia/lymphoma with high hyperdiploidy|B-lymphoblastic leukaemia/lymphoma with high hyperdiploidy]]
+|Disease
+|PENDING
 |
 |
 |
 |
+|HD
 |
 |
+|B-Lymphoblastic Leukemia/Lymphoma with Hyperdiploidy
+|Afia Hasnain, MBBS, PhD; Yassmine Akkari, PhD, FACMG
+|PENDING
 |
 |
 |-
-| || || || || || || || ||
+|[[HAEM5:B-lymphoblastic leukaemia/lymphoma with hypodiploidy|B-lymphoblastic leukaemia/lymphoma with hypodiploidy]]
-| ||
+|Disease
+|PENDING
+|
+|
+|
+|
+|HD
+|
+|
+|B-Lymphoblastic Leukemia/Lymphoma with Hypodiploidy
+|Ashwini Yenamandra PhD FACMG  Lisa Smith PhD FACMG  Yassmine Akkari PhD FACMG
+|Complete
+|
+|
 |-
-| || || || || || || || ||
+|[[HAEM5:B-lymphoblastic leukaemia/lymphoma with iAMP21|B-lymphoblastic leukaemia/lymphoma with iAMP21]]
-| ||
+|Disease
+|Holli Drendel
+|
+|
+|?Complete? Looks like tables need more editing.
+|
+|HD
+|
+|
+|B-Lymphoblastic Leukemia/Lymphoma with iAMP21 [but was completed as a 5th edition page by Holli]
+|Holli M. Drendel, PhD, FACMGG, Carolinas Pathology Group, Charlotte
+|?Complete
+|
+|
 |-
-| || || || || || || || ||
+|[[HAEM5:B-lymphoblastic leukaemia/lymphoma with BCR::ABL1 fusion|B-lymphoblastic leukaemia/lymphoma with BCR::ABL1 fusion]]
-| ||
+|Disease
+|PENDING
+|
+|
+|
+|
+|HD
+|
+|
+|B-Lymphoblastic Leukemia/Lymphoma with t(9;22)(q34.1;q11.2); BCR-ABL1
+|Afia Hasnain, MBBS, PhD; Yassmine Akkari, PhD, FACMG
+|PENDING
+|
+|
 |-
-| || || || || || || || ||
+|[[HAEM5:B-lymphoblastic leukaemia/lymphoma with BCR::ABL1-like features|B-lymphoblastic leukaemia/lymphoma with BCR::ABL1-like features]]
-| ||
+|Disease
+|PENDING
+|
+|
+|
+|
+|HD
+|
+|
+|B-Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like
+|Mark G. Evans, MD, University of California, Irvine  Fabiola Quintero-Rivera, MD, University of California, Irvine
+|Complete
+|
+|
 |-
-| || || || || || || || ||
+|[[HAEM5:B lymphoblastic leukaemia/lymphoma with KMT2A rearrangement|B lymphoblastic leukaemia/lymphoma with KMT2A rearrangement]]
-| ||
+|Disease
+|PENDING
+|
+|
+|
+|
+|HD
+|
+|
+|B-Lymphoblastic Leukemia/Lymphoma with t(v;11q23.3); KMT2A-Rearranged
+|Yassmine Akkari  Nicolas Millan
+|PENDING
+|
+|
 |-
-| || || || || || || || ||
+|[[HAEM5:B lymphoblastic leukaemia/lymphoma with ETV6::RUNX1 fusion|B lymphoblastic leukaemia/lymphoma with ETV6::RUNX1 fusion]]
-| ||
+|Disease
+|PENDING
+|
+|
+|
+|
+|HD
+|
+|
+|B lymphoblastic leukaemia/lymphoma with ETV6::RUNX1 fusion
+|Marilena Melas, PhD; Yassmine Akkari, PhD, FACMG   Cancer Category/Type    B-Lymphoblastic Leukemia/Lymphoma
+|PENDING
+|
+|
 |-
-| || || || || || || || ||
+|[[HAEM5:B-lymphoblastic leukaemia/lymphoma with ETV6::RUNX1-like features|B-lymphoblastic leukaemia/lymphoma with ETV6::RUNX1-like features]]
-| ||
+|Disease
+|
+|
+|
+|
+|
+|HD
+|
+|
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
 |-
-| || || || || || || || ||
+|[[HAEM5:B lymphoblastic leukaemia/lymphoma with TCF3::PBX1 fusion|B lymphoblastic leukaemia/lymphoma with TCF3::PBX1 fusion]]
-| ||
+|Disease
+|PENDING
+|
+|
+|
+|
+|HD
+|
+|
+|B-Lymphoblastic Leukemia/Lymphoma with t(1;19)(q23;p13.3); TCF3-PBX1
+|Binu Porath, PhD. Vanderbilt University Medical Center, Nashville, TN  Linda D. Cooley, MD, MBA. Children's Mercy Kansas City, Kansas City, MO
+|PENDING
+|
+|
 |-
-| || || || || || || || ||
+|[[HAEM5:B lymphoblastic leukaemia/lymphoma with IGH::IL3 fusion|B lymphoblastic leukaemia/lymphoma with IGH::IL3 fusion]]
-| ||
+|Disease
+|PENDING
+|
+|
+|
+|
+|HD
+|
+|
+|B-Lymphoblastic Leukemia/Lymphoma with t(5;14)(q31.1;q32.1); IGH/IL3
+|Binu Porath, PhD. Vanderbilt University Medical Center, Nashville, TN  Linda D. Cooley, MD, MBA. Children's Mercy Kansas City, Kansas City, MO
+|PENDING
+|
+|
 |-
-|Reactive B-cell rich lymphoid proliferations that can mimic lymphoma||Disease|| || || || || ||GC||
+|[[HAEM5:B lymphoblastic leukaemia/lymphoma with TCF3::HLF fusion|B lymphoblastic leukaemia/lymphoma with TCF3::HLF fusion]]
-| ||
+|Disease
+|
+|
+|
+|
+|
+|HD
+|
+|
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
 |-
-|IgG4-related disease||Disease|| || || || || ||GC||
+|[[HAEM5:B-lymphoblastic leukaemia/lymphoma with other defined genetic alterations|B-lymphoblastic leukaemia/lymphoma with other defined genetic alterations]]
-| ||
+|Disease
+|
+|
+|
+|
+|
+|HD
+|
+|
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
 |-
-|Unicentric Castleman disease||Disease|| || || || || ||GC||
+|[[HAEM5:B-lymphoblastic leukaemia/lymphoma, NOS|B-lymphoblastic leukaemia/lymphoma, NOS]]
-| ||
+|Disease
-|-
+|
-|Idiopathic multicentric Castleman disease||Disease|| || || || || ||GC||
+|
-| ||
+|
-|-
+|
-|KSHV/HHV8-associated multicentric Castleman disease||Disease||Sudha Arumugam, MD|| || || || ||GC||
+|
-| ||
+|HD
-|-
+|
-|Diffuse large B-cell lymphoma, NOS||Disease||Ashwini Yenamandra, PhD FACMG, Vanderbilt University Medical Center|| || || || ||GC||
+|
-| ||
+|NEW (No Prior)
-|-
+|NEW (No Prior)
-|T-cell/histiocyte-rich large B-cell lymphoma||Disease|| || || || || ||GC||
+|NEW (No Prior)
-| ||
+|NEW (No Prior)
-|-
+|NEW (No Prior)
-|Diffuse large B-cell lymphoma / high grade B-cell lymphoma with MYC and BCL2 rearrangements||Disease||Kate Berry, MBBS, BBus (Hons), Pathology Queensland|| || || || ||GC||
-| ||
-|-
-|ALK-positive large B-cell lymphoma||Disease||Manando Nakasaki, MD, PhD (University of California, Irvine)  Fabiola Quintero-Rivera, MD, FACMG (University of California, Irvine)|| || || || ||GC||
-| ||
-|-
-|Large B-cell lymphoma with IRF4 rearrangement||Disease||*Afia Hasnain, MBBS, PhD|| || || || ||GC||
-| ||
-|-
-|High grade B-cell lymphoma with 11q aberrations||Disease||Lauren Shealy, MD, Medical University of South Carolina  Daynna Wolff, PhD, Medical University of South Carolina|| || || || ||GC||
-| ||
-|-
-|Lymphomatoid granulomatosis||Disease|| || || || || ||GC||
-| ||
-|-
-|EBV-positive diffuse large B-cell lymphoma||Disease|| || || || || ||GC||
-| ||
-|-
-|Diffuse large B-cell lymphoma associated with chronic inflammation||Disease|| || || || || ||GC||
-| ||
-|-
-|Fibrin-associated large B-cell lymphoma||Disease|| || || || || ||GC||
-| ||
-|-
-|Fluid overload-associated large B-cell lymphoma||Disease|| || || || || ||GC||
-| ||
-|-
-|Plasmablastic lymphoma||Disease||Mark Evans, MD (University of California, Irvine)  Fabiola Quintero-Rivera, MD (University of California, Irvine)|| || || || ||GC||
-| ||
-|-
-|Primary large B-cell lymphoma of immune-privileged sites||Disease||Ashwini Yenamandra, PhD FACMG, Vanderbilt University Medical Center|| || || || ||GC||
-| ||
-|-
-|Primary cutaneous diffuse large B-cell lymphoma, leg type||Disease|| || || || || ||GC||
-| ||
-|-
-|Intravascular large B-cell lymphoma||Disease||Kate Berry, MBBS, BBus (Hons), Pathology Queensland|| || || || ||GC||
-| ||
-|-
-|Primary mediastinal large B-cell lymphoma||Disease|| || || || || ||GC||
-| ||
-|-
-|Mediastinal grey zone lymphoma||Disease|| || || || || ||GC||
-| ||
-|-
-|High-grade B-cell lymphoma, NOS||Disease||Aiko Otsubo, PhD, Indiana University|| || || || ||GC||
-| ||
-|-
-|Burkitt lymphoma||Disease||Becky Leung, MBBS (Hons), BSc, Pathology Queensland|| || || || ||GC||
-| ||
-|-
-|Primary effusion lymphoma||Disease|| || || || || ||GC||
-| ||
-|-
-|KSHV/HHV8-positive diffuse large B-cell lymphoma||Disease|| || || || || ||GC||
-| ||
-|-
-|KSHV/HHV8-positive germinotropic lymphoproliferative disorder||Disease|| || || || || ||GC||
-| ||
-|-
-|Hyperplasias arising in immune deficiency/dysregulation||Disease|| || || || || ||GC||
-| ||
-|-
-|Polymorphic lymphoproliferative disorders arising in immune deficiency / dysregulation||Disease||Anna Shestakova, MD, PhD, Fellow, University of Utah/ARUP Laboratories  Fabiola Quintero-Rivera, MD, Professor, University of California Irvine (UCI)|| || || || ||GC||
-| ||
-|-
-|EBV-positive mucocutaneous ulcer||Disease|| || || || || ||GC||
-| ||
-|-
-|Lymphomas arising in immune deficiency / dysregulation||Disease|| || || || || ||GC||
-| ||
-|-
-|Inborn error of immunity-associated lymphoid proliferations and lymphomas||Disease|| || || || || ||GC||
-| ||
-|-
-|Classic Hodgkin lymphoma||Disease||Patricia V. Hernandez, M.D., Washington University School of Medicine|| || || || ||GC||
-| ||
-|-
-|Nodular lymphocyte predominant Hodgkin lymphoma||Disease|| || || || || ||GC||
-| ||
 |-
+|RESOLVE 4th edition ALL-Related NON-WHO entities content
+|B-Lymphoblastic Leukemia/Lymphoma with t(4;14)(q35.2;q32); IGH/DUX4 + B-Lymphoblastic Leukemia/Lymphoma with dic(9;12)(p13;p13); PAX5/ETV6 + B-Lymphoblastic Leukemia/Lymphoma with ZNF384 Rearrangements + B-Lymphoblastic Leukemia/Lymphoma with IKZF1 Deletions + B-Lymphoblastic Leukemia/Lymphoma with TCF3 Rearrangements - Excluding t(1;19) and t(12;19) + B-Lymphoblastic Leukemia/Lymphoma with dic(9;20)(p13;q11)
+|ISSUE- FIX
+Resolve Non-WHO entities
 |
 |
@@ Line 886: / Line 1,468: @@
 |
 |
+|ISSUE - FIX
 |
 |
 |
 |-
-| || || || || || || || ||
+|[[HAEM5:Monoclonal B-cell lymphocytosis|Monoclonal B-cell lymphocytosis]]||Disease||PENDING; Shashirekha Shetty
+| || || || ||Shivani Golem (SG)
 | ||
+|Monoclonal B-cell Lymphocytosis
+|Tsigab Bahta Hagos (trainee) / Shashirekha Shetty
+|PENDING, 4/30/2024
+|
+|Assigned 12/19/2022 with completion date of 1/19/2023
 |-
-| || || || || || || || ||
+|[[HAEM5:Chronic lymphocytic leukaemia/small lymphocytic lymphoma|Chronic lymphocytic leukaemia/small lymphocytic lymphoma]]||Disease||Jaime Nagy, PhD, University of Iowa
-| ||
+Renee Eigsti, MD, Pathology Services of Kalamazoo
+Honey Reddi, PhD, Belay Diagnostics
+| || ||Complete|| ||SG|| ||
+|Already converted to 5th edition
+|Jamie Nagy, PhD, University of Iowa  Honey Reddi, PhD
+|
+|
+|
 |-
-| || || || || || || || ||
+|[[HAEM5:Hairy cell leukaemia|Hairy cell leukaemia]]||Disease||
-| ||
+| || || || ||SG|| ||
+|Hairy Cell Leukemia
+|Snehal Patel, MD, PhD
+|Complete
+|
+|
 |-
-| || || || || || || || ||
+|[[HAEM5:Splenic marginal zone lymphoma|Splenic marginal zone lymphoma]]||Disease||
-| ||
+| || || || ||SG|| ||
+|Splenic Marginal Zone Lymphoma
+|Snehal Patel, MD, PhD
+|Complete
+|
+|
 |-
-| || || || || || || || ||
+|[[HAEM5:Splenic diffuse red pulp small B-cell lymphoma|Splenic diffuse red pulp small B-cell lymphoma]]||Disease||
-| ||
+| || || || ||SG|| ||
+|Splenic Diffuse Red Pulp Small B-cell Lymphoma
+|Snehal Patel, MD, PhD
+|Complete
+|
+|
 |-
-| || || || || || || || ||
+|[[HAEM5:Splenic B-cell lymphoma/leukaemia with prominent nucleoli|Splenic B-cell lymphoma/leukaemia with prominent nucleoli]]
-| ||
+|Disease
+|
+|
+|
+|
+|
+|SG
+|
+|
+|Hairy Cell Leukemia Variant
+|Snehal Patel, MD, PhD
+|Complete
+|
+|
 |-
-| || || || || || || || ||
+|[[HAEM5:Lymphoplasmacytic lymphoma|Lymphoplasmacytic lymphoma]]
-| ||
+|Disease
+|PENDING
+|
+|
+|
+|
+|SG
+|
+|
+|(1) Lymphoplasmacytic Lymphoma + (2) Waldenstrom Macroglobulinemia
+|(1 and 2) Kapitolina Semenova, MD, Jack Reid, MD, Fabiola Quintero-Rivera, MD  Departments of Pathology, Laboratory Medicine, and Pediatrics, Division of Genetic and Genomic Medicine, University of California, Irvine (UCI)
+|Complete
+|4/12/2023 by FQR
+|
 |-
-| || || || || || || || ||
+|[[HAEM5:Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue|Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue]]
-| ||
+|Disease
+|PENDING
+|
+|
+|
+|
+|SG
+|
+|
+|Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT Lymphoma)
+|Whayoung Lee, MD (trainee), Fabiola Quintero-Rivera, MD, FACMG*
+Department of Pathology and Laboratory Medicine and *Pediatrics, School of Medicine, University of California Irvine (UCI)
+|Complete
+|4/12/23 by FQR
+|
 |-
-| || || || || || || || ||
+|[[HAEM5:Primary cutaneous marginal zone lymphoma|Primary cutaneous marginal zone lymphoma]]
-| ||
+|Disease
+|
+|
+|
+|
+|
+|SG
+|
+|
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
 |-
-| || || || || || || || ||
+|[[HAEM5:Nodal marginal zone lymphoma|Nodal marginal zone lymphoma]]
-| ||
+|Disease
+|PENDING
+|
+|
+|
+|
+|SG
+|
+|
+|Nodal Marginal Zone Lymphoma
+|Andrew Ly, DO and Shivani Golem, PhD, FACMG
+|Complete
+|5/28/2021
+|
 |-
-| || || || || || || || ||
+|[[HAEM5:Paediatric nodal marginal zone lymphoma|Paediatric nodal marginal zone lymphoma]]
-| ||
+|Disease
+|PENDING
+|
+|
+|
+|
+|SG
+|
+|
+|Paediatric Nodal Marginal Zone Lymphoma
+|* Kathleen M. Schieffer, PhD * Ruthann Pfau, PhD
+|Complete
+|11/11/2020
+|
 |-
-| || || || || || || || ||
+|[[HAEM5:In situ follicular B-cell neoplasm|In situ follicular B-cell neoplasm]]
-| ||
+|Disease
+|Rachel D. Burnside, PhD, MBA, FACMGG
+|7/28/2023
+|
+|Pending
+|
+|SG
+|
+|
+|In Situ Follicular Neoplasia
+|Rachel D. Burnside, PhD, MBA, FACMGG
+|Pending
+|
+|
 |-
-| || || || || || || || ||
+|[[HAEM5:Follicular lymphoma|Follicular lymphoma]]
-| ||
+|Disease
+|Rachel D. Burnside, PhD, MBA, FACMGG
+|7/28/2023
+|
+|Pending
+|
+|SG
+|
+|Author also needs to correlate with 4th edition disease "Testicular Follicular Lymphoma", which is no longer a separate entity
+|(1) Follicular Lymphoma + (2) Testicular Follicular Lymphoma
+|(1 and 2) Ruthann Pfau, PhD, FACMG, Nationwide Children's Hospital  Rachel D. Burnside, PhD, MBA, FACMG, University of Florida
+|Pending
+|
+|
 |-
-| || || || || || || || ||
+|[[HAEM5:Paediatric-type follicular lymphoma|Paediatric-type follicular lymphoma]]
-| ||
+|Disease
+|PENDING
+|
+|
+|
+|
+|SG
+|
+|
+|Paediatric-Type Follicular Lymphoma
+|*Kathleen M. Schieffer, PhD *Ruthann Pfau, PhD, FACMG
+|Complete
+|8/16/2020
+|
 |-
-| || || || || || || || ||
+|[[HAEM5:Duodenal-type follicular lymphoma|Duodenal-type follicular lymphoma]]
-| ||
+|Disease
+|Rachel D. Burnside, PhD, MBA, FACMGG
+|7/28/2023
+|
+|Pending
+|
+|SG
+|
+|
+|Duodenal-Type Follicular Lymphoma
+|No prior content
+|
+|
+|
 |-
-| || || || || || || || ||
+|[[HAEM5:Primary cutaneous follicle centre lymphoma|Primary cutaneous follicle centre lymphoma]]
-| ||
+|Disease
-|-
+|PENDING
-| || || || || || || || ||
+|
-| ||
+|
-|-
+|
-| || || || || || || || ||
+|
-| ||
+|SG
-|-
+|
-| || || || || || || || ||
+|
-| ||
+|Primary Cutaneous Follicle Centre Lymphoma
-|-
+|Linlin Gao, MD, PhD and Shivani Golem, PhD, FACMG
-| || || || || || || || ||
+|Complete
-| ||
+|09/10/2022
-|-
+|
-| || || || || || || || ||
-| ||
-|-
-| || || || || || || || ||
-| ||
-|-
-| || || || || || || || ||
-| ||
-|-
-| || || || || || || || ||
-| ||
-|-
-| || || || || || || || ||
-| ||
 |-
+|[[HAEM5:In situ mantle cell neoplasm|In situ mantle cell neoplasm]]
+|Disease
+|PENDING
+|
+|
+|
 |
+|SG
 |
 |
+|In Situ Mantle Cell Neoplasia
+|Rina Kansal, MD; Versiti Blood Center of Wisconsin
+|Complete
+|7/26/2022
 |
+|-
+|[[HAEM5:Mantle cell lymphoma|Mantle cell lymphoma]]
+|Disease
+|PENDING
 |
 |
 |
 |
+|SG
 |
 |
+|Mantle Cell Lymphoma
+|Mahsa Khanlari, MD and  Zhenya Tang, MD, PhD  The University Of Texas MD Anderson Cancer Center, Department of Hematopathology, Houston, Texas
+|Pending
 |
+|Target completion date 8/15/20
 |-
-| || || || || || || || ||
+|[[HAEM5:Leukaemic non-nodal mantle cell lymphoma|Leukaemic non-nodal mantle cell lymphoma]]
-| ||
+|Disease
-|-
+|
-| || || || || || || || ||
+|
-| ||
-|-
-| || || || || || || || ||
-| ||
-|-
-| || || || || || || || ||
-| ||
-|-
-| || || || || || || || ||
-| ||
-|-
-| || || || || || || || ||
-| ||
-|-
-| || || || || || || || ||
-| ||
-|-
-| || || || || || || || ||
-| ||
-|-
 |
 |
 |
+|SG
 |
 |
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
+|-
+|[[HAEM5:Transformations of indolent B-cell lymphomas|Transformations of indolent B-cell lymphomas]]
+|Disease
 |
 |
@@ Line 1,011: / Line 1,751: @@
 |
 |
+|SG
 |
+|Include content on chronic myelomonocytic leukemia in transformation and refractory anaemia with excess blasts in transformation
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
 |-
-| || || || || || || || ||
+|[[HAEM5:Diffuse large B-cell lymphoma, NOS|Diffuse large B-cell lymphoma, NOS]]||Disease||PENDING
-| ||
+| || || || ||GC|| ||
+|Diffuse Large B-cell Lymphoma, Not Otherwise Specified
+|Ashwini Yenamandra, PhD FACMG, Vanderbilt University Medical Center
+|Pending
+|
+|Requested to update 14022022
 |-
-| || || || || || || || ||
+|[[HAEM5:T-cell/histiocyte-rich large B-cell lymphoma|T-cell/histiocyte-rich large B-cell lymphoma]]||Disease|| || || || || ||GC|| ||
-| ||
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
 |-
-|Monoclonal B-cell lymphocytosis||Disease|| || || || || ||SP||
+|[[HAEM5:Diffuse large B-cell lymphoma / high grade B-cell lymphoma with MYC and BCL2 rearrangements|Diffuse large B-cell lymphoma / high grade B-cell lymphoma with MYC and BCL2 rearrangements]]||Disease||PENDING
-| ||
+| || || || ||GC|| ||
+|High-Grade B-cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements
+|Kate Berry, MBBS, BBus (Hons), Pathology Queensland
+|Complete
+|24/02/2022
+|
 |-
-|Chronic lymphocytic leukaemia/small lymphocytic lymphoma||Disease||Jamie Nagy, PhD, University of Iowa  Honey Reddi, PhD|| || || || ||SP||
+|[[HAEM5:ALK-positive large B-cell lymphoma|ALK-positive large B-cell lymphoma]]||Disease||PENDING
-| ||
+| || || || ||GC|| ||
+|ALK-Positive Large B-cell Lymphoma
+|Manando Nakasaki, MD, PhD (University of California, Irvine)  Fabiola Quintero-Rivera, MD, FACMG (University of California, Irvine)
+|Pending
+|
+|Nakasaki Manando removed March 2022 due to no progress/contact 1y. Added Nakasaki Manando back n 8/29/22 based on newer email communication (Jennelle's note). 2021 template added. FQR emailed Manando on 4/12/23
 |-
-|Hairy cell leukaemia||Disease||*Snehal Patel, MD, PhD|| || || || ||SP||
+|[[HAEM5:Large B-cell lymphoma with IRF4 rearrangement|Large B-cell lymphoma with IRF4 rearrangement]]||Disease||PENDING
-| ||
+| || || || ||GC|| ||
+|Large B-cell Lymphoma with IRF4 Rearrangement
+|Afia Hasnain, MBBS, PhD
+|Complete
+|5/26/2021
+|
 |-
-|Splenic marginal zone lymphoma||Disease||*Snehal Patel, MD, PhD|| || || || ||SP||
+|[[HAEM5:High grade B-cell lymphoma with 11q aberrations|High grade B-cell lymphoma with 11q aberrations]]||Disease||PENDING
-| ||
+| || || || ||GC|| ||
+|Burkitt-Like Lymphoma with 11q Aberration
+|Lauren Shealy, MD, Medical University of South Carolina  Daynna Wolff, PhD, Medical University of South Carolina
+|Comlete
+|27/01/2022
+|
 |-
-|Splenic diffuse red pulp small B-cell lymphoma||Disease||*Snehal Patel, MD, PhD|| || || || ||SP||
+|[[HAEM5:Lymphomatoid granulomatosis|Lymphomatoid granulomatosis]]||Disease|| || || || || ||GC|| ||
-| ||
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
 |-
-|Splenic B-cell lymphoma/leukaemia with prominent nucleoli||Disease||*Snehal Patel, MD, PhD|| || || || ||SP||
+|[[HAEM5:EBV-positive diffuse large B-cell lymphoma|EBV-positive diffuse large B-cell lymphoma]]||Disease||Fnu Monika (trainee) + Andrew Siref as mentor
-| ||
+|3/22/24|| ||Pending|| ||GC|| ||
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
 |-
-|Lymphoplasmacytic lymphoma||Disease||Kapitolina Semenova, MD, Jack Reid, MD, Fabiola Quintero-Rivera, MD  Departments of Pathology, Laboratory Medicine, and *Pediatrics, Division of Genetic and Genomic Medicine, University of California, Irvine (UCI)|| || || || ||SP||
+|[[HAEM5:Diffuse large B-cell lymphoma associated with chronic inflammation|Diffuse large B-cell lymphoma associated with chronic inflammation]]||Disease|| || || || || ||GC|| ||
-| ||
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
 |-
-|Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue||Disease|| || || || || ||SP||
+|[[HAEM5:Fibrin-associated large B-cell lymphoma|Fibrin-associated large B-cell lymphoma]]||Disease||PENDING
-| ||
+| || || || ||GC|| ||Note: previously a subset DLBCL assoc with chronic inflam
+|Originally called Fibrin-Associated Diffuse Large B-cell Lymphoma; NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
 |-
-|Primary cutaneous marginal zone lymphoma||Disease|| || || || || ||SP||
+|[[HAEM5:Fluid overload-associated large B-cell lymphoma|Fluid overload-associated large B-cell lymphoma]]||Disease|| || || || || ||GC|| ||
-| ||
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
 |-
-|Nodal marginal zone lymphoma||Disease||Andrew Ly, DO and Shivani Golem, PhD, FACMG|| || || || ||SP||
+|[[HAEM5:Plasmablastic lymphoma|Plasmablastic lymphoma]]||Disease||PENDING
-| ||
+| || || || ||GC|| ||
+|Plasmablastic Lymphoma
+|Mark Evans, MD (University of California, Irvine)  Fabiola Quintero-Rivera, MD (University of California, Irvine)
+|Complete
+|28/03/2022
+|
 |-
-|Paediatric nodal marginal zone lymphoma||Disease||* Kathleen M. Schieffer, PhD * Ruthann Pfau, PhD|| || || || ||SP||
+|[[HAEM5:Primary large B-cell lymphoma of immune-privileged sites|Primary large B-cell lymphoma of immune-privileged sites]]||Disease||PENDING
-| ||
+| || || || ||GC|| ||
+|(1) Diffuse Large B-cell Lymphoma, Not Otherwise Specified + (2) Primary Diffuse Large B-cell Lymphoma of the CNS
+|(1) Ashwini Yenamandra, PhD FACMG, Vanderbilt University Medical Center + (2) Laveniya Satgunaseelan, FRCPA, Department of Neuropathology, Royal Prince Alfred Hospital
+|(1) Pending + (2) Complete
+|(1) Not ready + (2) 03/28/22
+|For "Diffuse Large B-cell Lymphoma, Not Otherwise Specified" page from Ash, Greg requested to update 14022022
 |-
-|In situ follicular B-cell neoplasm||Disease||Rachel D. Burnside, PhD, MBA, FACMGG|| || || || ||SP||
+|[[HAEM5:Primary cutaneous diffuse large B-cell lymphoma, leg type|Primary cutaneous diffuse large B-cell lymphoma, leg type]]||Disease|| || || || || ||GC|| ||
-| ||
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
 |-
-|Follicular lymphoma||Disease||Ruthann Pfau, PhD, FACMG, Nationwide Children's Hospital  Rachel D. Burnside, PhD, MBA, FACMG, University of Florida|| || || || ||SP||
+|[[HAEM5:Intravascular large B-cell lymphoma|Intravascular large B-cell lymphoma]]||Disease||PENDING
-| ||
+| || || || ||GC|| ||
+|Intravascular Large B-cell Lymphoma
+|Kate Berry, MBBS, BBus (Hons), Pathology Queensland, Greg Corboy
+|Complete
+|9/1/22
+|Emailed 28/3/2022 for progress update
 |-
-|Paediatric-type follicular lymphoma||Disease||*Kathleen M. Schieffer, PhD *Ruthann Pfau, PhD, FACMG|| || || || ||SP||
+|[[HAEM5:Primary mediastinal large B-cell lymphoma|Primary mediastinal large B-cell lymphoma]]||Disease|| || || || || ||GC|| ||
-| ||
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
 |-
-|Duodenal-type follicular lymphoma||Disease|| || || || || ||SP||
+|[[HAEM5:Mediastinal grey zone lymphoma|Mediastinal grey zone lymphoma]]||Disease|| || || || || ||GC|| ||
-| ||
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
 |-
-|Primary cutaneous follicle centre lymphoma||Disease||Linlin Gao, MD, PhD and Shivani Golem, PhD, FACMG|| || || || ||SP||
+|[[HAEM5:High-grade B-cell lymphoma, NOS|High-grade B-cell lymphoma, NOS]]||Disease||PENDING
-| ||
+| || || || ||GC|| ||
+|High-Grade B-cell Lymphoma, Not Otherwise Specified (NOS)
+|Aiko Otsubo, PhD, Indiana University, Holli Drendel
+|Complete
+|16/11/2021
+|
 |-
-|In situ mantle cell neoplasm||Disease||Rina Kansal, MD; Versiti Blood Center of Wisconsin|| || || || ||SP||
+|[[HAEM5:Burkitt lymphoma|Burkitt lymphoma]]||Disease||PENDING
-| ||
+| || || || ||GC|| ||
+|Burkitt Lymphoma
+|Becky Leung, MBBS (Hons), BSc, Pathology Queensland
+|Complete
+|28/06/2021
+|
 |-
-|Mantle cell lymphoma||Disease||* Mahsa Khanlari, MD * Zhenya Tang, MD, PhD  The University Of Texas MD Anderson Cancer Center, Department of Hematopathology, Houston, Texas|| || || || ||SP||
+|[[HAEM5:Primary effusion lymphoma|Primary effusion lymphoma]]||Disease|| || || || || ||GC|| ||
-| ||
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
 |-
-|Leukaemic non-nodal mantle cell lymphoma||Disease||<br />|| || || || ||SP||
+|[[HAEM5:KSHV/HHV8-positive diffuse large B-cell lymphoma|KSHV/HHV8-positive diffuse large B-cell lymphoma]]||Disease|| || || || || ||GC|| ||
-| ||
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
 |-
-|Transformations of indolent B-cell lymphomas||Disease|| || || || || ||SP||
+|[[HAEM5:KSHV/HHV8-positive germinotropic lymphoproliferative disorder|KSHV/HHV8-positive germinotropic lymphoproliferative disorder]]||Disease|| || || || || ||GC|| ||
-| ||
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
 |-
-|Cold agglutinin disease||Disease|| || || || || ||SP||
+|[[HAEM5:Hyperplasias arising in immune deficiency/dysregulation|Hyperplasias arising in immune deficiency/dysregulation]]||Disease||FIX ISSUE! (on 5th edition page instructions say "encompassing non-destructive post-transplant lymphoproliferative disorders, among others"). "Non-Destructive Post-Transplant Lymphoproliferative Disorders" was a HAME4 page but no content.  What are "among others" from HAEM4 to see if we need to pull prior content into 5th edition page.|| || || || ||GC|| ||
-| ||
+|
+|
+|
+|
+|
 |-
-|IgM monoclonal gammopathy of undetermined significance||Disease|| || || || || ||SP||
+|[[HAEM5:Polymorphic lymphoproliferative disorders arising in immune deficiency / dysregulation|Polymorphic lymphoproliferative disorders arising in immune deficiency / dysregulation]]||Disease||FIX ISSUE! (on 5th edition page instructions say "This page was converted to the new template on 2023-12-07. The original page can be found at [[HAEM4:Polymorphic Post-Transplant Lymphoproliferative Disorders]].
-| ||
+Note: encompassing polymorphic PTLD, other iatrogenic immunodef-assoc lympho disorders, among others)"
+| || || || ||GC|| ||
+|Polymorphic Post-Transplant Lymphoproliferative Disorders
+|Anna Shestakova, MD, PhD, Fellow, University of Utah/ARUP Laboratories  Fabiola Quintero-Rivera, MD, Professor, University of California Irvine (UCI)
+|Completed
+|26/4/2022
+|
 |-
-|Non-IgM monoclonal gammopathy of undetermined significance||Disease|| || || || || ||SP||
+|[[HAEM5:EBV-positive mucocutaneous ulcer|EBV-positive mucocutaneous ulcer]]||Disease|| || || || || ||GC|| ||
-| ||
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
 |-
-|Monoclonal gammopathy of renal significance||Disease|| || || || || ||SP||
+|[[HAEM5:Lymphomas arising in immune deficiency / dysregulation|Lymphomas arising in immune deficiency / dysregulation]]||Disease||FIX ISSUE! (on 5th edition page instructions say "encompassing monomorphic PTLD, classic HL PTLD, lymphomas assoc with HIV infection, among others"|| || || || ||GC|| ||
-| ||
+|
+|
+|
+|
+|
 |-
-|Immunoglobulin-related (AL) amyloidosis||Disease||Heather E. Williams, PhD, MS, PgD, ErCLG|| || || || ||SP||
+|[[HAEM5:Inborn error of immunity-associated lymphoid proliferations and lymphomas|Inborn error of immunity-associated lymphoid proliferations and lymphomas]]||Disease||FIX ISSUE! (on 5th edition page instructions say "Editor said this overview page is a match. [Immunodeficiency-Associated Lymphoproliferative Disorders] [Lymphoproliferative diseases associated with primary immune disorders]") - last link name above is not a known page in haem4 or haem5.|| || || || ||GC|| ||
-| ||
+|
+|
+|
+|
+|
 |-
-|Monoclonal immunoglobulin deposition disease||Disease||Chen Yang, MD, PhD, University of Michigan|| || || || ||SP||
+|[[HAEM5:Classic Hodgkin lymphoma|Classic Hodgkin lymphoma]]||Disease||PENDING
-| ||
+| || || ||
+|GC|| ||Note: author needs to merge Nodular Sclerosis Classic Hodgkin Lymphoma, Lymphocyte-Rich Classic Hodgkin Lymphoma, Mixed Cellularity Classic Hodgkin Lymphoma, Lymphocyte-Depleted Classic Hodgkin Lymphoma
+|(1) Lymphocyte-Rich Classic Hodgkin Lymphoma + (2) Nodular Sclerosis Classic Hodgkin Lymphoma + (3) Mixed Cellularity Classic Hodgkin Lymphoma + (4) Lymphocyte-Depleted Classic Hodgkin Lymphoma
+|(1) Patricia V. Hernandez, M.D., Washington University School of Medicine and Holli Drendel + (2) Xiaolin Hu, PhD, Sema4 OpCo Inc. + (3 and 4) Patricia V. Hernandez
+|Pending + Completed (03/21/22)
+|Not completed for checking (1, 3 and 4) + 03/21/22 (2)
+|
 |-
-|Mu heavy chain disease||Disease|| || || || || ||SP||
+|[[HAEM5:Nodular lymphocyte predominant Hodgkin lymphoma|Nodular lymphocyte predominant Hodgkin lymphoma]]||Disease|| || || || || ||GC|| ||
-| ||
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
 |-
-|Gamma heavy chain disease||Disease||Manisha Brahmbhatt-Sutariya  Asst. Professor, Dept. of Pathology and Human Anatomy  Technical Supervisor, Clinical Genetics Laboratory  Loma Linda University, Medical Center, CA|| || || || ||SP||
+|[[HAEM5:Cold agglutinin disease|Cold agglutinin disease]]
-| ||
+|Disease
+|
+|
+|
+|
+|
+|SG
+|
+|
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
 |-
-|Alpha heavy chain disease||Disease|| || || || || ||SP||
+|[[HAEM5:IgM monoclonal gammopathy of undetermined significance|IgM monoclonal gammopathy of undetermined significance]]||Disease|| || || || || ||SG|| ||
-| ||
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
 |-
-|Plasmacytoma||Disease|| || || || || ||SP||
+|[[HAEM5:Non-IgM monoclonal gammopathy of undetermined significance|Non-IgM monoclonal gammopathy of undetermined significance]]||Disease|| || || || || ||SG|| ||
-| ||
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
 |-
-|Plasma cell myeloma / multiple myeloma||Disease||*Huan Mo, MD, MS *Zhenya Tang, MD, PhD  The University Of Texas MD Anderson Cancer Center, Department of Hematopathology, Houston, Texas|| || || || ||SP||
+|[[HAEM5:Monoclonal gammopathy of renal significance|Monoclonal gammopathy of renal significance]]||Disease|| || || || || ||SG
 | ||
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
 |-
-|Plasma cell neoplasms with associated paraneoplastic syndrome||Disease||Sohini Anand, MBBS   Tharanga Niroshini Senaratne, PhD|| || || || ||SP||
+|[[HAEM5:Immunoglobulin-related (AL) amyloidosis|Immunoglobulin-related (AL) amyloidosis]]||Disease||PENDING
+| || || || ||SG
 | ||
+|Primary Amyloidosis
+|Heather E. Williams, PhD, MS, PgD, ErCLG
+|?PENDING<br />
+|
+|
 |-
-|Kikuchi-Fujimoto disease||Disease|| || || || || ||SP||
+|[[HAEM5:Monoclonal immunoglobulin deposition disease|Monoclonal immunoglobulin deposition disease]]||Disease||PENDING
+| || || || ||SG
 | ||
+|Light Chain and Heavy Chain Deposition Disease
+|Chen Yang, MD, PhD, University of Michigan
+|Complete
+|10/15/2022
+|
 |-
-|Autoimmune lymphoproliferative syndrome||Disease|| || || || || ||SP||
+|[[HAEM5:Mu heavy chain disease|Mu heavy chain disease]]||Disease|| || || || || ||SG
 | ||
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
 |-
-|Indolent T-lymphoblastic proliferation||Disease|| || || || || ||SP||
+|[[HAEM5:Gamma heavy chain disease|Gamma heavy chain disease]]||Disease||PENDING
+| || || || ||SG
 | ||
+|Gamma Heavy Chain Disease
+|Manisha Brahmbhatt-Sutariya  Asst. Professor, Dept. of Pathology and Human Anatomy  Technical Supervisor, Clinical Genetics Laboratory  Loma Linda University, Medical Center, CA
+|Complete
+|5/26/2021
+|
 |-
-|T-prolymphocytic leukaemia||Disease|| || || || || ||SP||
+|[[HAEM5:Alpha heavy chain disease|Alpha heavy chain disease]]||Disease|| || || || || ||SG
 | ||
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
 |-
-|T-large granular lymphocytic leukaemia||Disease||*Michelle Don, MD, MS|| || || || ||SP||
+|[[HAEM5:Plasmacytoma|Plasmacytoma]]||Disease||PENDING
-| ||
+| || || ||
+|SG
+| ||author needs to include Solitary plasmacytoma of bone, Extraosseous plasmacytoma (extramedullary) (v4 page did not have content on ccga)
+|NEW (No Prior) - no content on version 4 page "Plasmacytoma' originally assigned to Zhenya Tang
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
 |-
-|NK-large granular lymphocytic leukaemia||Disease||Michelle Don, MD|| || || || ||SP||
+|[[HAEM5:Plasma cell myeloma / multiple myeloma|Plasma cell myeloma / multiple myeloma]]||Disease||PENDING
-| ||
+| || || || ||SG
+| ||Note: author needs to include Plasma_Cell_Myeloma_Variants content in this page
+|(1) Plasma Cell Myeloma + (2) Plasma Cell Myeloma Variants
+|(1) Huan Mo, MD, MS and Zhenya Tang, MD, PhD  The University Of Texas MD Anderson Cancer Center, Department of Hematopathology, Houston, Texas + (2) Fariborz Rashid-Kolvear, PhD, FACMG, FCCMG
+|Pending
+|
+|
 |-
-|Adult T-cell leukaemia/lymphoma||Disease||Prasad R. Kopparapu, PhD and Ferrin C. Wheeler, PhD, FACMG  Vanderbilt University Medical Center|| || || || ||SP||
+|[[HAEM5:Plasma cell neoplasms with associated paraneoplastic syndrome|Plasma cell neoplasms with associated paraneoplastic syndrome]]||Disease||PENDING
-| ||
+| || || ||
+|SG
+| ||Note: author needs to include POEMS, TEMPI, and look for AESOP content
+|(1) POEMS Syndrome + (2) TEMPI Syndrome
+|(1 and 2) Sohini Anand, MBBS   Tharanga Niroshini Senaratne, PhD
+|?PENDING
+|
+|
 |-
-|Sezary syndrome||Disease||Madison E. Hannay, DO, Medical University of South Carolina  Tingting Barrett, MD, Medical University of South Carolina  Daynna J. Wolff, PhD, Medical University of South Carolina|| || || || ||SP||
+|Disease (5th Edition)
-| ||
+|Page Type
+|Author (5th Edition) (Note: please indicate trainees in parenthesis)
+|Date Assigned to Author (5th Edition)
+|Target Completion Date (5th Edition)
+|Content Status (5th Edition) (Pending or Complete)
+|Date Completed by Author (5th Edition)
+|Associate Editor
+|Date of Last Editor Review (5th Edition)
+|Notes (5th Edition)
+|Correlated Prior Disease Name (4th Edition)
+|Correlated Prior Author (4th Edition)
+|Prior Content Status (4th Edition) (Pending or Complete)
+|Prior Date of Last Editor Review (4th Edition)
+|Prior Notes (4th Edition)
 |-
-|Aggressive NK-cell leukaemia||Disease||Shanelle De Lancy, MD, Shashirekha Shetty, PhD|| || || || ||SP||
+|CHAPTER 5 (T-CELL AND NK-CELL LYMPHOID PROLIFERATIONS AND LYMPHOMAS)
-| ||
+|
+----<br />
+|
+----<br />
+|
+----<br />
+|
+----<br />
+|
+----<br />
+|
+----<br />
+|
+----<br />
+|
+----<br />
+|
+----<br />
+|
+----<br />
+|
+----<br />
+|
+----<br />
+|
+----<br />
+|
+----<br />
 |-
-|Primary cutaneous CD4-positive small or medium T-cell lymphoproliferative disorder||Disease|| || || || || ||SP||
+|[[HAEM5:Kikuchi-Fujimoto disease|Kikuchi-Fujimoto disease]]||Disease|| || || || || ||Sumi Kitahara (SK)
 | ||
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
 |-
-|Primary cutaneous acral CD8-positive T-cell lymphoproliferative disorder||Disease|| || || || || ||SP||
+|[[HAEM5:Autoimmune lymphoproliferative syndrome|Autoimmune lymphoproliferative syndrome]]||Disease||Aviv Oren, MD (trainee), Karin Miller, MD
-| ||
+|3/25/2024
+| || || ||SK|| ||
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
 |-
-|Mycosis fungoides||Disease||Jane Scribner, MD and Daynna J. Wolff, PhD|| || || || ||SP||
+|[[HAEM5:Indolent T-lymphoblastic proliferation|Indolent T-lymphoblastic proliferation]]||Disease|| || || || || ||SK|| ||
-| ||
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
 |-
-|Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Lymphomatoid papulosis||Disease|| || || || || ||SP||
+|[[HAEM5:T-lymphoblastic leukaemia / lymphoma, NOS|T-lymphoblastic leukaemia / lymphoma, NOS]]||Disease|| || || || || ||SK|| ||
-| ||
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
 |-
-|Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Primary cutaneous anaplastic large cell lymphoma||Disease||Theresa Spivey, MD, Shashirekha Shetty, PhD|| || || || ||SP||
+|[[HAEM5:Early T-precursor lymphoblastic leukaemia / lymphoma|Early T-precursor lymphoblastic leukaemia / lymphoma]]
-| ||
+|Disease
+|Fei Yang, MD
+|
+|
+|Pending
+|
+|SK
+|
+|
+|Early T-Cell Precursor Lymphoblastic Leukemia
+|Fei Yang, MD, FACMG, Kaiser Permanente Northwest
+|Pending
+|
+|
 |-
-|Subcutaneous panniculitis-like T-cell lymphoma||Disease|| || || || || ||SP||
+|[[HAEM5:T-prolymphocytic leukaemia|T-prolymphocytic leukaemia]]
-| ||
+|Disease
+|Parastou Tizro, MD (trainee);
+Sumire Kitahara, MD
+|3/17/2024
+|
+|Pending
+|
+|SK
+|
+|
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
 |-
-|Primary cutaneous gamma/delta T-cell lymphoma||Disease|| || || || || ||SP||
+|[[HAEM5:T-large granular lymphocytic leukaemia|T-large granular lymphocytic leukaemia]]||Disease||Michelle Don, MD, MS
-| ||
+|3/17/2024
+|6/30/24
+|Pending
+| ||SK|| ||
+|T-cell Large Granular Lymphocytic Leukemia
+|Michelle Don, MD, MS
+|Pending
+|
+|
 |-
-|Primary cutaneous CD8-positive aggressive epidermotropic cytotoxic T-cell lymphoma||Disease|| || || || || ||SP||
+|[[HAEM5:NK-large granular lymphocytic leukaemia|NK-large granular lymphocytic leukaemia]]||Disease||Hailee St. Louis (trainee);
-| ||
+Michelle Don, MD, MS
+|3/17/2024
+|6/30/24
+|Pending
+| ||SK|| ||
+|Chronic Lymphoproliferative Disorder of NK Cells
+|Michelle Don, MD
+|Pending
+|
+|
 |-
-|Primary cutaneous peripheral T-cell lymphoma, NOS||Disease|| || || || || ||SP||
+|[[HAEM5:Adult T-cell leukaemia/lymphoma|Adult T-cell leukaemia/lymphoma]]||Disease||
-| ||
+| || || || ||SK|| ||
+|Adult T-cell Leukemia/Lymphoma
+|Prasad R. Kopparapu, PhD and Ferrin C. Wheeler, PhD, FACMG  Vanderbilt University Medical Center
+|?Pending
+|
+|
 |-
-|Indolent T-cell lymphoma of the gastrointestinal tract||Disease||Derick Okwan-Duodu MD, PhD; Sumire Kitahara, MD|| || || || ||SP||
+|[[HAEM5:Sezary syndrome|Sezary syndrome]]||Disease||Daynna J. Wolff, PhD
-| ||
+|3/22/2024
+| || || ||SK|| ||
+|Sézary Syndrome
+|Madison E. Hannay, DO, Medical University of South Carolina  Tingting Barrett, MD, Medical University of South Carolina  Daynna J. Wolff, PhD, Medical University of South Carolina
+|Pending
+|
+|
 |-
-|Indolent NK-cell lymphoproliferative disorder of the gastrointestinal tract||Disease|| || || || || ||SP||
+|[[HAEM5:Aggressive NK-cell leukaemia|Aggressive NK-cell leukaemia]]||Disease||PENDING
-| ||
+| || || || ||SK|| ||
+|Aggressive NK-cell Leukemia
+|Shanelle De Lancy, MD, Shashirekha Shetty, PhD
+|?Pending
+|
+|
 |-
-|Enteropathy-associated T-cell lymphoma||Disease||*Derick Okwan-Duodu, MD, PhD *Sumire Kitahara, MD|| || || || ||SP||
+|[[HAEM5:Primary cutaneous CD4-positive small or medium T-cell lymphoproliferative disorder|Primary cutaneous CD4-positive small or medium T-cell lymphoproliferative disorder]]||Disease||Amanda Xu, MD/MSc
-| ||
+|3/19/2024
+| ||Pending
+| ||SK|| ||
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
 |-
-|Monomorphic epitheliotropic intestinal T-cell lymphoma||Disease||Derick Okwan-Duodu MD, PhD; Sumire Kitahara, MD|| || || || ||SP||
+|[[HAEM5:Primary cutaneous acral CD8-positive T-cell lymphoproliferative disorder|Primary cutaneous acral CD8-positive T-cell lymphoproliferative disorder]]||Disease||Ahmed Eladely (trainee),
-| ||
+Andrew Siref, MD
+|4/12/2024
+| ||Pending
+| ||SK|| ||
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
 |-
-|Intestinal T-cell lymphoma, NOS||Disease||Derick Okwan MD, PhD (Stanford Medicine, CA)   Sumire Kitahara MD (Cedars-Sinai, CA)|| || || || ||SP||
+|[[HAEM5:Mycosis fungoides|Mycosis fungoides]]||Disease||Daynna J. Wolff, PhD
-| ||
+|3/22/2024
+| || || ||SK|| ||
+|Mycosis Fungoides
+|Jane Scribner, MD and Daynna J. Wolff, PhD
+|Pending
+|
+|
 |-
-|Hepatosplenic T-cell lymphoma||Disease||*Michelle Don, MD, MS|| || || || ||SP||
+|[[HAEM5:Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Lymphomatoid papulosis|Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Lymphomatoid papulosis]]||Disease|| || || || || ||SK|| ||
-| ||
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
 |-
-|ALK-positive anaplastic large cell lymphoma||Disease|| || || || || ||SP||
+|[[HAEM5:Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Primary cutaneous anaplastic large cell lymphoma|Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Primary cutaneous anaplastic large cell lymphoma]]||Disease||PENDING
-| ||
+| || || || ||SK|| ||
+|Primary Cutaneous Anaplastic Large Cell Lymphoma
+|Theresa Spivey, MD, Shashirekha Shetty, PhD
+|Pending
+|
+|
 |-
-|ALK-negative anaplastic large cell lymphoma||Disease||Miguel Gonzalez Mancera, MD  Sumire Kitahara, MD  Cedars-Sinai, Los Angeles, CA|| || || || ||SP||
+|[[HAEM5:Subcutaneous panniculitis-like T-cell lymphoma|Subcutaneous panniculitis-like T-cell lymphoma]]||Disease||Raniah Alamri (Hemepath trainee)
-| ||
+|3/19/2024
+| ||Pending
+| ||SK|| ||
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
 |-
-|Breast implant-associated anaplastic large cell lymphoma||Disease||Derick Okwan-Duodu, MD, PhD; Sumire Kitahara, MD  Cedars-Sinai Medical Center|| || || || ||SP||
+|[[HAEM5:Primary cutaneous gamma/delta T-cell lymphoma|Primary cutaneous gamma/delta T-cell lymphoma]]||Disease||Mahzad Azimpouran (trainee); Sumire Kitahara, MD
-| ||
+| || || || ||SK|| ||
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
 |-
-|Nodal TFH cell lymphoma, angioimmunoblastic-type||Disease||* Sara Akhavanfard, M.D., Ph.D. * Ruthann Pfau, Ph.D., FACMG|| || || || ||SP||
+|[[HAEM5:Primary cutaneous CD8-positive aggressive epidermotropic cytotoxic T-cell lymphoma|Primary cutaneous CD8-positive aggressive epidermotropic cytotoxic T-cell lymphoma]]||Disease||Ahmed Eladely (trainee),
-| ||
+Andrew Siref, MD
+|4/12/2024|| ||Pending
+| ||SK|| ||
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
 |-
-|Nodal TFH cell lymphoma, follicular-type||Disease|| || || || || ||SP||
+|[[HAEM5:Primary cutaneous peripheral T-cell lymphoma, NOS|Primary cutaneous peripheral T-cell lymphoma, NOS]]||Disease|| || || || || ||SK|| ||
-| ||
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
 |-
-|Nodal TFH cell lymphoma, NOS||Disease||Hans Magne Hamnvåg, MD  Kamran Mirza, MD, PhD|| || || || ||SP||
+|[[HAEM5:Indolent T-cell lymphoma of the gastrointestinal tract|Indolent T-cell lymphoma of the gastrointestinal tract]]||Disease||
-| ||
+| || || || ||SK|| ||
+|Indolent T-cell Lymphoproliferative Disorder of the Gastrointestinal Tract
+|Derick Okwan-Duodu MD, PhD; Sumire Kitahara, MD
+|Pending
+|
+|
 |-
-|Peripheral T-cell lymphoma, NOS||Disease|| || || || || ||SP||
+|[[HAEM5:Indolent NK-cell lymphoproliferative disorder of the gastrointestinal tract|Indolent NK-cell lymphoproliferative disorder of the gastrointestinal tract]]||Disease|| || || || || ||SK|| ||
-| ||
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
 |-
-|EBV-positive nodal T- and NK-cell lymphoma||Disease|| || || || || ||SP||
+|[[HAEM5:Enteropathy-associated T-cell lymphoma|Enteropathy-associated T-cell lymphoma]]||Disease||Fnu Monika, MBBS (trainee),
-| ||
+Andrew Siref, MD
+|3/20/2024
+| ||Pending|| ||SK|| ||
+|Enteropathy-Associated T-cell Lymphoma
+|*Derick Okwan-Duodu, MD, PhD *Sumire Kitahara, MD
+|Complete
+|1/21/2021
+|
 |-
-|Extranodal NK/T-cell lymphoma||Disease|| || || || || ||SP||
+|[[HAEM5:Monomorphic epitheliotropic intestinal T-cell lymphoma|Monomorphic epitheliotropic intestinal T-cell lymphoma]]||Disease||Fnu Monika, MBBS (trainee),
-| ||
+Andrew Siref, MD
+|3/20/2024
+| ||Pending|| ||SK|| ||
+|Monomorphic Epitheliotropic Intestinal T-cell Lymphoma
+|Derick Okwan-Duodu MD, PhD; Sumire Kitahara, MD
+|Pending
+|
+|
 |-
-|Severe mosquito bite allergy||Disease|| || || || || ||SP||
+|[[HAEM5:Intestinal T-cell lymphoma, NOS|Intestinal T-cell lymphoma, NOS]]||Disease||
-| ||
+| || || || ||SK|| ||
+|Intestinal T-cell Lymphoma, Not Otherwise Specified (NOS)
+|Derick Okwan MD, PhD (Stanford Medicine, CA)   Sumire Kitahara MD (Cedars-Sinai, CA)
+|Complete
+|9/26/2022
+|
 |-
-|Hydroa vacciniforme lymphoproliferative disorder||Disease|| || || || || ||SP||
+|[[HAEM5:Hepatosplenic T-cell lymphoma|Hepatosplenic T-cell lymphoma]]||Disease||Forough Sargolzaeiaval (trainee);
-| ||
+Michelle Don, MD, MS
+|3/19/2024
+|6/30/24
+|Pending
+| ||SK|| ||
+|Hepatosplenic T-cell Lymphoma
+|Michelle Don, MD, MS
+|Complete
+|1/21/2021
+|
 |-
-|Systemic chronic active EBV disease||Disease|| || || || || ||SP||
+|[[HAEM5:ALK-positive anaplastic large cell lymphoma|ALK-positive anaplastic large cell lymphoma]]||Disease||Miguel Gonzalez Mancera, MD (trainee)
-| ||
+Sumire Kitahara, MD
+| || ||Pending
+| ||SK|| ||
+|Anaplastic Large Cell Lymphoma, ALK-Positive
+|Miguel Gonzalez Mancera, MD
+Sumire Kitahara, MD
+Cedars-Sinai, Los Angeles, CA
+|Complete
+|09/23/2022
+|
 |-
-|Systemic EBV-positive T-cell lymphoma of childhood||Disease||*Lisa A. Lansdon, PhD & Linda D. Cooley, MD, MBA|| || || || ||SP||
+|[[HAEM5:ALK-negative anaplastic large cell lymphoma|ALK-negative anaplastic large cell lymphoma]]||Disease||Miguel Gonzalez Mancera, MD (trainee)
-| ||
+Sumire Kitahara, MD
+| || ||Pending
+| ||SK|| ||
+|Anaplastic Large Cell Lymphoma, ALK-Negative
+|Miguel Gonzalez Mancera, MD  Sumire Kitahara, MD  Cedars-Sinai, Los Angeles, CA
+|Complete
+|09/23/2022
+|
 |-
-|Follicular dendritic cell sarcoma||Disease||Anna Heimes Dillon, MD and Shivani Golem, PhD, FACMG|| || || || ||SP||
+|[[HAEM5:Breast implant-associated anaplastic large cell lymphoma|Breast implant-associated anaplastic large cell lymphoma]]||Disease||Lynne Abruzzo, MD, PhD
-| ||
+|4/1/2024
+| ||Pending|| ||SK|| ||
+|Breast Implant-Associated Anaplastic Large Cell Lymphoma
+|Derick Okwan-Duodu, MD, PhD; Sumire Kitahara, MD  Cedars-Sinai Medical Center
+|Pending
+|
+|
 |-
-|EBV-positive inflammatory follicular dendritic cell sarcoma||Disease|| || || || || ||SP||
+|[[HAEM5:Nodal TFH cell lymphoma, angioimmunoblastic-type|Nodal TFH cell lymphoma, angioimmunoblastic-type]]||Disease||Rachel Burnside, PhD||7/28/2023
-| ||
+| ||Pending|| ||SK|| ||prior authors not available
+|Angioimmunoblastic T-cell Lymphoma
+|Sara Akhavanfard, M.D., Ph.D. and Ruthann Pfau, Ph.D., FACMG
+|Pending
+|
+|
 |-
-|Fibroblastic reticular cell tumour||Disease|| || || || || ||SP||
+|[[HAEM5:Nodal TFH cell lymphoma, follicular-type|Nodal TFH cell lymphoma, follicular-type]]||Disease||Rachel Burnside, PhD||7/28/2023
-| ||
+| ||Pending|| ||SK|| ||
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
 |-
-|Intranodal palisaded myofibroblastoma||Disease|| || || || || ||SP||
+|[[HAEM5:Nodal TFH cell lymphoma, NOS|Nodal TFH cell lymphoma, NOS]]||Disease||
-| ||
+| || || || ||SK|| ||
+|Nodal Peripheral T-cell Lymphoma with T Follicular Helper Phenotype
+|Hans Magne Hamnvåg, MD  Kamran Mirza, MD, PhD
+|Pending
+|
+|
 |-
-|Littoral cell angioma||Disease|| || || || || ||SP||
+|[[HAEM5:Peripheral T-cell lymphoma, NOS|Peripheral T-cell lymphoma, NOS]]||Disease||Bo Hong, MD
-| ||
+|6/25/2023
+| || || ||SK|| ||
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
 |-
-|Splenic hamartoma||Disease|| || || || || ||SP||
+|[[HAEM5:EBV-positive nodal T- and NK-cell lymphoma|EBV-positive nodal T- and NK-cell lymphoma]]||Disease||Fnu Monika, MBBS (trainee), Andrew Siref, MD||3/22/2024|| ||Pending|| ||SK|| ||
-| ||
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
 |-
-|Sclerosing angiomatoid nodular transformation (SANT) of spleen||Disease|| || || || || ||SP||
+|[[HAEM5:Extranodal NK/T-cell lymphoma|Extranodal NK/T-cell lymphoma]]||Disease||Amanda Xu, MD/MSc
-| ||
+|3/19/2024
+| ||Pending
+| ||SK|| ||
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
 |-
-|B-lymphoblastic leukaemia/lymphoma||Disease|| || || || || ||YA||
+|[[HAEM5:Severe mosquito bite allergy|Severe mosquito bite allergy]]||Disease|| || || || || ||SK|| ||
-| ||
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
 |-
-|B-lymphoblastic leukaemia/lymphoma with high hyperdiploidy||Disease||Afia Hasnain, MBBS, PhD; Yassmine Akkari, PhD, FACMG|| || || || ||YA||
+|[[HAEM5:Hydroa vacciniforme lymphoproliferative disorder|Hydroa vacciniforme lymphoproliferative disorder]]||Disease|| || || || || ||SK|| ||
-| ||
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
 |-
-|B-lymphoblastic leukaemia/lymphoma with hypodiploidy||Disease||Ashwini Yenamandra PhD FACMG  Lisa Smith PhD FACMG  Yassmine Akkari PhD FACMG|| || || || ||YA||
+|[[HAEM5:Systemic chronic active EBV disease|Systemic chronic active EBV disease]]||Disease||Karin Miller, MD
-| ||
+|3/25/2024
+| || || ||SK|| ||
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
 |-
-|B-lymphoblastic leukaemia/lymphoma with iAMP21||Disease||Holli M. Drendel, PhD, FACMGG, Carolinas Pathology Group, Charlotte|| || || || ||YA||
+|[[HAEM5:Systemic EBV-positive T-cell lymphoma of childhood|Systemic EBV-positive T-cell lymphoma of childhood]]||Disease||Karin Miller, MD
-| ||
+|3/25/2024
+| || || ||SK|| ||prior authors not available
+|Systemic EBV-Positive T-cell Lymphoma of Childhood
+|Lisa A. Lansdon, PhD and Linda D. Cooley, MD, MBA
+|Complete
+|11/21/2021
+|
 |-
-|B-lymphoblastic leukaemia/lymphoma with BCR::ABL1 fusion||Disease||Afia Hasnain, MBBS, PhD; Yassmine Akkari, PhD, FACMG|| || || || ||YA||
+|CHAPTER 6 (STROMA-DERIVED NEOPLASMS OF LYMPHOID TISSUES)
-| ||
+|
+----<br />
+|
+----<br />
+|
+----<br />
+|
+----<br />
+|
+----<br />
+|
+----<br />
+|
+----<br />
+|
+----<br />
+|
+----<br />
+|
+----<br />
+|
+----<br />
+|
+----<br />
+|
+----<br />
+|
+----<br />
 |-
-|B-lymphoblastic leukaemia/lymphoma with BCR::ABL1-like features||Disease||Mark G. Evans, MD, University of California, Irvine  Fabiola Quintero-Rivera, MD, University of California, Irvine|| || || || ||YA||
+|[[HAEM5:Follicular dendritic cell sarcoma|Follicular dendritic cell sarcoma]]
-| ||
+|Disease
+|PENDING
+|
+|
+|
+|
+|GC
+|
+|
+|Follicular Dendritic Cell Sarcoma
+|Anna Heimes Dillon, MD and Shivani Golem, PhD, FACMG
+|?Pending
+|
+|
 |-
-|B lymphoblastic leukaemia/lymphoma with KMT2A rearrangement||Disease||Yassmine Akkari  Nicolas Millan|| || || || ||YA||
+|[[HAEM5:EBV-positive inflammatory follicular dendritic cell sarcoma|EBV-positive inflammatory follicular dendritic cell sarcoma]]
-| ||
+|Disease
+|
+|
+|
+|
+|
+|GC
+|
+|
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
 |-
-|B lymphoblastic leukaemia/lymphoma with ETV6::RUNX1 fusion||Disease||Marilena Melas, PhD; Yassmine Akkari, PhD, FACMG   Cancer Category/Type    B-Lymphoblastic Leukemia/Lymphoma|| || || || ||YA||
+|[[HAEM5:Fibroblastic reticular cell tumour|Fibroblastic reticular cell tumour]]
-| ||
+|Disease
+|
+|
+|
+|
+|
+|GC
+|
+|
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
 |-
-|B-lymphoblastic leukaemia/lymphoma with ETV6::RUNX1-like features||Disease|| || || || || ||YA||
+|[[HAEM5:Intranodal palisaded myofibroblastoma|Intranodal palisaded myofibroblastoma]]
-| ||
+|Disease
+|
+|
+|
+|
+|
+|GC
+|
+|
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
 |-
-|B lymphoblastic leukaemia/lymphoma with TCF3::PBX1 fusion||Disease||Binu Porath, PhD. Vanderbilt University Medical Center, Nashville, TN  Linda D. Cooley, MD, MBA. Children's Mercy Kansas City, Kansas City, MO|| || || || ||YA||
+|[[HAEM5:Littoral cell angioma|Littoral cell angioma]]
-| ||
+|Disease
+|
+|
+|
+|
+|
+|GC
+|
+|
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
 |-
-|B lymphoblastic leukaemia/lymphoma with IGH::IL3 fusion||Disease||Binu Porath, PhD. Vanderbilt University Medical Center, Nashville, TN  Linda D. Cooley, MD, MBA. Children's Mercy Kansas City, Kansas City, MO|| || || || ||YA||
+|[[HAEM5:Splenic hamartoma|Splenic hamartoma]]
-| ||
+|Disease
+|
+|
+|
+|
+|
+|GC
+|
+|
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
 |-
-|B lymphoblastic leukaemia/lymphoma with TCF3::HLF fusion||Disease|| || || || || ||YA||
+|[[HAEM5:Sclerosing angiomatoid nodular transformation (SANT) of spleen|Sclerosing angiomatoid nodular transformation (SANT) of spleen]]
-| ||
+|Disease
+|
+|
+|
+|
+|
+|GC
+|
+|
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
 |-
-|B-lymphoblastic leukaemia/lymphoma with other defined genetic alterations||Disease|| || || || || ||YA||
+|CHAPTER 7 (GENETIC TUMOUR SYNDROMES)
-| ||
+|
+----<br />
+|
+----<br />
+|
+----<br />
+|
+----<br />
+|
+----<br />
+|
+----<br />
+|
+----<br />
+|
+----<br />
+|
+----<br />
+|
+----<br />
+|
+----<br />
+|
+----<br />
+|
+----<br />
+|
+----<br />
 |-
-|B-lymphoblastic leukaemia/lymphoma, NOS||Disease|| || || || || ||YA||
+|[[HAEM5:Fanconi anaemia|Fanconi anaemia]]||Disease|| || || || || ||NA|| ||
-| ||
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
 |-
-|T-lymphoblastic leukaemia / lymphoma, NOS||Disease|| || || || || ||YA||
+|[[HAEM5:Bloom syndrome|Bloom syndrome]]||Disease|| || || || || ||NA|| ||
-| ||
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
 |-
-|Early T-precursor lymphoblastic leukaemia / lymphoma||Disease||Fei Yang, MD, FACMG, Kaiser Permanente Northwest|| || || || ||YA||
+|[[HAEM5:Ataxia-telangiectasia syndrome|Ataxia-telangiectasia syndrome]]||Disease|| || || || || ||NA|| ||
-| ||
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
+|NEW (No Prior)
 |-
-|Fanconi anaemia||Disease|| || || || || ||NA||
+|[[HAEM5:RASopathies|RASopathies]]||Disease|| || || || || ||NA|| ||
-| ||
+|NEW (No Prior)
-|-
+|NEW (No Prior)
-|Bloom syndrome||Disease|| || || || || ||NA||
+|NEW (No Prior)
-| ||
+|NEW (No Prior)
-|-
+|NEW (No Prior)
-|Ataxia-telangiectasia syndrome||Disease|| || || || || ||NA||
-| ||
-|-
-|RASopathies||Disease|| || || || || ||NA||
-| ||
 |}